Document:

exv10w10

 

Exhibit 10.10

EMPLOYMENT AGREEMENT

(Non CEO)

     THIS AGREEMENT is executed as of this 1st day of April, 2007, by and between
TomoTherapy Incorporated, a Wisconsin corporation (the “Company”), and Gustavo Hugo
Olivera, an individual (“Employee”).

RECITALS

     The Company desires to employ Employee, and Employee desires to be employed by or continued to
be employed by the Company, on the terms and conditions set forth herein.

     The parties believe it is in their best interests to make provision for certain aspects of
their relationship during and after the period in which Employee is employed by the Company.

     NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants
contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged by the Company and Employee,

     IT IS HEREBY AGREED AS FOLLOWS:

ARTICLE I

EMPLOYMENT

     1.1 Term of Employment. The Company employs Employee, and Employee accepts employment
by the Company, for the period commencing on the date hereof and ending on March 31, 2008, subject
to earlier termination as hereinafter set forth in Article III (the “Employment Term”).
Following the expiration of the Employment Term, the Employment Term shall be automatically renewed
for successive one-year periods (collectively, the “Renewal Terms”; individually, a
“Renewal Term”) unless, at least 60 days prior to the expiration of the Employment Term or
the then current Renewal Term, either party provides the other with a written notice of intention
not to renew, in which case Employee’s employment with the Company, and the Company’s obligations
hereunder shall terminate as of the end of the Employment Term or said Renewal Term, as applicable,
except to the extent specifically provided herein. If the Employment Term is renewed, the terms of
this Agreement during such Renewal Term shall be the same as the terms in effect immediately prior
to such renewal, subject to any such changes or modifications as mutually may be agreed between the
parties as evidenced in a written instrument signed by both the Company and Employee.

     1.2 Position and Duties. Employee shall be employed in the position of Vice President
of Research, and shall be subject to the authority of, and shall report to, the Company’s Chief
Operating Officer. Employee’s duties and responsibilities shall include all those customarily
attendant to the position of Vice President of Research, and such other duties and responsibilities
as may be assigned by the Company’s Chief Operating Officer. Employee shall devote Employee’s
entire business time, loyalty, attention and energies exclusively to the

 

 

business interests of the Company while employed by the Company, and shall perform his duties
and responsibilities diligently and to the best of his ability.

ARTICLE II

COMPENSATION AND OTHER BENEFITS

     2.1 Base Salary. The Company shall pay Employee an annual salary of $245,260
(“Base Salary”), payable in accordance with the normal payroll practices of the Company.

     2.2 Performance Bonus. Employee will be eligible to earn an annual performance based
bonus for that portion of each full calendar year during which Employee is employed by the Company
(a “Bonus Year”), the terms and conditions of which as well as Employee’s entitlement
thereto shall be determined annually in the sole discretion of the Company’s Board of Directors or
an authorized committee thereof (the “Performance Bonus”). Employee must commence
employment with the Company before October 1 of the Bonus Year in order to be eligible for a
Performance Bonus for that Bonus Year. Any Performance Bonus payable hereunder shall be paid
following the Bonus Year not later than the earlier of (i) 30 days following the Company’s receipt
of its annual audited financial report or (ii) April 15.

     2.3 Benefit Plans. Employee will be eligible to participate in the Company’s
retirement plans that are qualified under Section 401(a) of the Internal Revenue Code of 1986, as
amended, and in the Company’s welfare benefit plans that are generally applicable to all executive
employees of the Company (the “Plans”), in accordance with the terms and conditions
thereof. The Company shall provide Employee with: (a) portable term life insurance with a death
benefit equal to twice the sum of Employee’s current Base Salary and target Performance Bonus;
provided, however, that the minimum benefit shall equal at least $500,000; and (b) long-term
disability insurance with an annual benefit equal to at least 75% of the sum of Employee’s Base
Salary and target Performance Bonus.

     2.4 Expenses. The Company shall reimburse Employee for all reasonable expenses
incurred in the course of the performance of Employee’s duties and responsibilities pursuant to
this Agreement and consistent with the Company’s policies with respect to travel, entertainment and
miscellaneous expenses, and the requirements with respect to the reporting of such expenses.

     2.5 Vacation. Employee shall be entitled to a maximum of four weeks of vacation in
any calendar year in accordance with the Company’s general vacation policies for similarly situated
executive employees.

ARTICLE III

TERMINATION

     3.1 Right to Terminate; Automatic Termination.

          (a) Termination by Company Without Cause. Subject to Section 3.2, the Company may
terminate Employee’s employment and all of the obligations under this Agreement at any time and for
any reason.

2

 

          (b) Termination by Employee for Good Reason. Subject to Section 3.2, Employee may
terminate his employment obligation hereunder for “Good Reason” (as hereinafter defined) if
Employee gives written notice thereof to the Company (which notice shall specify the grounds upon
which such notice is given) and the Company fails, within 30 days of receipt of such notice, to
cure or rectify the grounds for such Good Reason termination set forth in such notice. “Good
Reason” shall mean any of the following: (i) a material reduction of the Employee’s duties and
responsibilities hereunder; (ii) a material change in the working conditions of the Employee
including, without limitation, relocation of Employee’s principal workplace over 50 miles from the
Company’s existing workplace, without the consent of Employee; or (iii) the Company’s material
breach of the Agreement.

          (c) Termination by Company For Cause. Subject to Section 3.2, the Company may
terminate Employee’s employment and all of the Company’s obligations under this Agreement at any
time “For Cause” (as defined below) by giving notice to Employee stating the basis for such
termination, effective immediately upon giving such notice or at such other time thereafter as the
Company may designate. “For Cause” shall mean any of the following: (i) Employee has
breached this Agreement or any other agreement to which Employee and the Company are parties or has
breached any other obligation or duty owed to the Company, which breach remains uncured to the
satisfaction of the Board of Directors of the Company for 30 days after Employee receives notice
thereof from the Board of Directors; (ii) Employee has engaged in harassing or offensive conduct
which has the potential to give rise to an action under federal, state or local laws for
discrimination in employment; (iii) Employee repeatedly interacts with staff or subordinates in a
demeaning and unprofessional or abusive manner; (iv) Employee has committed gross negligence,
willful misconduct or any violation of law or the Company’s Comprehensive Corporate Compliance
Program in the performance of Employee’s duties to the Company; (v) Employee has taken any action
likely to result in material discredit to or material loss of business, reputation or goodwill of
the Company; (vi) Employee has failed to follow instructions from the officer or body to whom
Employee reports concerning the operations or business of the Company; (vii) Employee has committed
a felony deemed by the Company to be adverse to its best interest or reputation; (viii) Employee
has misappropriated funds or property of the Company; or (ix) Employee has attempted to obtain a
personal profit from any transaction in which the Company has an interest, and which constitutes a
corporate opportunity of the Company or is adverse to the interests of the Company, unless the
transaction was approved in writing by the Company’s Board of Directors after full disclosure of
all details relating to such transaction.

          (d) Termination Upon Death or Disability. Subject to Section 3.2, Employee’s
employment and the Company’s obligations under this Agreement shall terminate: (i) automatically,
effective immediately and without any notice being necessary, upon Employee’s death; and (ii) in
the event of the disability of Employee, by the Company giving notice of termination to Employee.
For purposes of this Agreement, “disability” means the inability of Employee, due to a
physical or mental impairment, for 180 days (whether or not consecutive) during any period of 360
days to perform, with reasonable accommodation, the essential functions of the work contemplated by
this Agreement. In the event of any dispute as to whether Employee is disabled, the matter shall
be determined by the Company’s Board of Directors in consultation with a physician satisfactory to
the Company, and Employee shall cooperate with the efforts to make such determination. Any such
determination shall be conclusive and binding

3

 

on the parties. Any determination of disability under this Section 3.1(c) is not intended to
alter any benefits any party may be entitled to receive under any long-term disability insurance
policy carried by either the Company or Employee with respect to Employee, which benefits shall be
governed solely by the terms of any such insurance policy. Nothing in this subsection shall be
construed as limiting or altering any of Employee’s rights under state workers compensation laws or
state or Federal family and medical leave laws. 

     3.2 Rights Upon Termination.

          (a) Section 3.1(a) and 3.1(b) Termination. If Employee’s employment is terminated
pursuant to Section 3.1(a) or 3.1(b) hereof or upon expiration of this Agreement pursuant to the
Company’s notice of its intention not to renew pursuant to Section 1.1, Employee shall have no
further rights against the Company hereunder, except the Company will no later than the date that
is six (6) months and one (1) day after the date of termination of employment or expiration of the
Employment Term or Renewal Term, as the case may be, or the last day of such shorter period upon
such termination of employment or expiration of the Employment Term or Renewal Term, as the case
may be, that is sufficient to avoid the imposition of additional tax under Section 409A(a)(1)(B) of
the Internal Revenue Code of 1986, as amended (the “Code”), or any other taxes or penalties imposed
under Section 409A of the Code (the “Deferred Payment Date”):

     (i) pay Employee a lump-sum severance payment (the “Severance Payment”) in an amount
equal to the sum of: (i) 12 months’ of Employee’s annual base salary as in effect on the
date of termination; and (ii) the average of the two annual Performance Bonuses paid to
Employee for the two years preceding the year in which such termination occurs;

     (ii) pay the COBRA premium for health care coverage for Employee and Employee’s spouse
and children, as applicable and to the extent eligible (the “Severance Benefits”), provided
that Employee properly elects COBRA continuation coverage, for the twelve (12)-month period
immediately following the date of such termination of Employee’s employment. On the Deferred
Payment Date, the Company will pay Employee an amount equal to the Severance Benefits for
the period beginning on the date of your termination of employment and ending on the
Deferred Payment Date; and

     (iii) pay up to $10,000 for outplacement services.

          (b) Section 3.1(c) Termination. If Employee’s employment is terminated pursuant to
Sections 3.1(c) hereof, or if Employee quits employment notwithstanding the terms of this
Agreement, Employee or Employee’s estate shall have no further rights against the Company
hereunder, except for the right to receive (i) any unpaid Base Salary with respect to the period
prior to the effective date of termination, and (ii) reimbursement of expenses to which Employee is
entitled under Section 2.4 hereof.

          (c) Section 3.1(d) Termination. If Employee’s employment is terminated pursuant to
Sections 3.1(d) hereof, Employee’s estate shall have no further rights against the

4

 

Company hereunder, except for the right to receive (i) any unpaid Base Salary with respect to
the period prior to the effective date of termination, (ii) reimbursement of expenses to which
Employee is entitled under Section 2.4 hereof, and (iii) payment of the COBRA premium for health
care coverage for Employee’s spouse and children, as applicable and to the extent eligible (the
"Severance Benefits”), provided that Employee’s estate properly elects COBRA continuation coverage,
for the twelve (12) month period immediately following the date of such termination of Employee’s
employment.

          (d) Termination Pursuant to a Change of Control. If, within three (3) months before
or twenty four (24) months following a Change of Control, the Company terminates Employee’s
employment without Cause pursuant to Section 3.1(a) or Employee terminates his employment for Good
Reason pursuant to Section 3.1(b), Employee shall have no further rights against the Company
hereunder, except the Company will no later than the date that is six (6) months and one (1) day
after the date of termination of employment, or the last day of such shorter period upon such
termination of employment that is sufficient to avoid the imposition of additional tax under
Section 409A(a)(1)(B) of the Internal Revenue Code of 1986, as amended, or any other taxes or
penalties imposed under Section 409A of the Code:

     (i) pay Employee a lump-sum severance payment (the “Severance Payment”) in an amount
equal to the sum of: (i) 2.0 times Employee’s annual base salary as in effect on the date
of termination; and (ii) 2.0 times the greater of (x) the average of the two annual bonuses
paid to Employee for the two years preceding the year in which such termination occurs or
(y) the target bonus for the year in which such termination occurs;

     (ii) pay the COBRA premium for health care coverage for Employee and Employee’s spouse
and children, as applicable and to the extent eligible (the “Severance Benefits”), provided
that Employee properly elects COBRA continuation coverage, for the 24-month period
immediately following the date of such termination of Employee’s employment. On the Deferred
Payment Date, the Company will pay Employee an amount equal to the Severance Benefits for
the period beginning on the date of your termination of employment and ending on the
Deferred Payment Date; and

     (iii) pay up to $10,000 for outplacement services.

As used herein, the term “Change in Control” shall mean (1) any “person” (as such term is
used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the
“beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities
of the Company representing 50% or more of the total voting power represented by the Company’s then
outstanding voting securities, other than in a private financing transaction approved by the Board
of Directors; (2) the direct or indirect sale or exchange by the shareholders of the Company of all
or substantially all of the stock, other than to an affiliate of the Company as determined by the
Board of Directors of the Company; (3) a merger or consolidation in which the Company is a party
and in which the shareholders of the Company before such merger or consolidation do not retain,
directly or indirectly, at least a majority of the beneficial interest in the voting stock of the
Company after such transaction; or (4) the sale or disposition by the Company of all or
substantially all the Company’s assets.

5

 

          (e) Exclusive Remedy. To the extent permitted by applicable law, the payments
contemplated by this Section 3.2 shall constitute the exclusive and sole remedy for any termination
of Employee’s employment by the Company (whether pursuant to, or in violation of, the terms of this
Agreement). Employee covenants not to assert or pursue any remedies, other than an action to
enforce the payments due to Employee under this Agreement, at law or in equity, with respect to any
termination of employment, and shall execute a release and waiver on such terms and conditions as
the Company may require as a condition of entitlement to such payments.

          (f) Limitation of Benefits. If any payments or benefits payable to the employee under
this Agreement or otherwise would be subject to the excise tax under Section 4999 of the Code, such
payments and/or benefits will be reduced to the extent necessary so that no amount will be subject
to such excise tax; provided that such reduction will only occur if the employee will be in a more
favorable, after-tax position than if no such reduction was made.

ARTICLE IV

GENERAL PROVISIONS

     4.1 Notices. Any and all notices provided for in this Agreement shall be given in
writing and shall be deemed given to a party at the earlier of (i) when actually delivered to such
party, or (ii) when mailed to such party by registered or certified mail (return receipt requested)
or sent to such party by courier, confirmed by receipt, and addressed to such party at the address
designated below for such party as follows (or to such other address for such party as such party
may have substituted by notice pursuant to this Section 4.1):

	 	 	 	 	 
	 

	 	(a)
	 	If to the Company:
	 

	 	 	 	TomoTherapy Incorporated
	 

	 	 	 	1240 Deming Way
	 

	 	 	 	Madison, WI 53717
	 

	 	 	 	Attn: General Counsel
	 
	 	 	 	 
	 

	 	(b)
	 	If to Employee:
	 

	 	 	 	6221 Dominion Drive
	 

	 	 	 	Madison, WI 53718
	 

	 	 	 	Attn: Gustavo Hugo Olivera

     4.2 Entire Agreement. This Agreement contains the entire understanding and the full
and complete agreement of the parties and supersedes and replaces any prior understandings and
agreements among the parties, with respect to the subject matter hereof.

     4.3 Amendment. This Agreement may be altered, amended or modified only in a writing,
signed by both of the parties hereto. Headings included in this Agreement are for convenience only
and are not intended to limit or expand the rights of the parties hereto. References to Sections
herein shall mean sections of the text of this Agreement, unless otherwise indicated.

     4.4 Assignability. This Agreement and the rights and duties set forth herein may not
be assigned by Employee, but may be assigned by the Company, in whole or in part. This

6

 

Agreement shall be binding on and inure to the benefit of each party and such party’s
respective heirs, legal representatives, successors and assigns.

     4.5 Severability. If any court of competent jurisdiction determines that any
provision of this Agreement is invalid or unenforceable, then such invalidity or unenforceability
shall have no effect on the other provisions hereof, which shall remain valid, binding and
enforceable and in full force and effect, and such invalid or unenforceable provision shall be
construed in a manner so as to give the maximum valid and enforceable effect to the intent of the
parties expressed therein.

     4.6 Arbitration. Any controversy, dispute or claim arising out of or relating to this
Agreement (including, but not limited to, any claim regarding the scope or effect of this Section
and any claim that this Section is invalid or unenforceable), or the breach hereof, shall be
settled by a single arbitrator in binding arbitration conducted in Milwaukee, Wisconsin in
accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”)(or
such other arbitration service as the parties may agree upon), and judgment upon the award rendered
by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator’s
decision shall be in writing. In addition to the Commercial Arbitration Rules of the AAA and
unless otherwise agreed to by the parties, the following rules shall apply:

          (a) Each party shall be entitled to discovery exclusively by the following means: (i) requests
for admission, (ii) requests for production of documents, (iii) up to 15 written interrogatories
(with any subpart to be counted as a separate interrogatory), and (iv) depositions of no more than
six individuals.

          (b) Unless the arbitrator finds that delay is reasonably justified or as otherwise agreed to
by the parties, all discovery shall be completed, and the arbitration hearing shall commence within
five months after the appointment of the arbitrator.

          (c) Unless the arbitrator finds that delay is reasonably justified, the hearing will be
completed, and an award rendered within 30 days of commencement of the hearing.

The arbitrator’s authority shall include the ability to render equitable types of relief and, in
such event, any aforesaid court may enter an order enjoining and/or compelling such actions or
relief ordered or as found by the arbitrator. The arbitrator also shall make a determination
regarding which party’s legal position in any such controversy or claim is the more substantially
correct (the “Prevailing Party”) and the arbitrator shall require the other party to pay the legal
and other professional fees and costs incurred by the Prevailing Party in connection with such
arbitration proceeding and any necessary court action. However, notwithstanding the foregoing, the
parties expressly agree that a court of competent jurisdiction may enter a temporary restraining
order or an order enjoining a breach of Article IV of this Agreement pending a final award or
further order by the arbitrator. Such remedy, however, shall be cumulative and nonexclusive, and
shall be in addition to any other remedy to which the parties may be entitled.

     4.7 Waiver of Breach. The waiver by either party of the breach of any provision of
this Agreement shall not operate or be construed as a waiver of any subsequent breach by either
party.

7

 

     4.8 Governing Law; Construction. This Agreement shall be governed by the internal
laws of the State of Wisconsin, without regard to any rules of construction concerning the party
responsible for the drafting hereof.

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year written
above.

	 	 	 	 	 
	EMPLOYEE:	 	COMPANY:
	 
	 	 	 	 
	 	 	TomoTherapy Incorporated
	 
	 	 	 	 
	/s/ Gustavo Hugo Olivera

	 	By:	 	/s/ Frederick A. Robertson, M.D.
	 

	 	 	 	 
	Gustavo Hugo Olivera	 	Frederick A. Robertson, M.D.
	 	 	Chief Executive Officer

8exv10w11

Table of Contents

Exhibit 10.11

DEVELOPMENT AND OEM SUPPLY AGREEMENT

TOMOTHERAPY

AGREEMENT entered into as of this 27th day of January 2003, by and between Analogic
Corporation (“ANALOGIC”), a Massachusetts corporation, having its principal place of business at 8
Centennial Drive, Peabody, Massachusetts and TomoTherapy Incorporated (“TOMOTHERAPY”), a Wisconsin
corporation, having its principal place of business at 1240 Deming Way Madison, Wisconsin (ANALOGIC
and TOMOTHERAPY hereinafter may be referred to individually as a “Party” and collectively as
“Parties”).

     WHEREAS TOMOTHERAPY has designed and is manufacturing an integrated radiation therapy
and imaging system (the “Product”);

     WHEREAS
ANALOGIC is a leading designer and manufacturer of systems and sub-systems used in,
among other things, computed tomography systems;

     WHEREAS TOMOTHERAPY wishes to engage ANALOGIC to design, manufacture, and/or supply those
systems and sub-systems shown in the Specifications (Exhibit 1) to be designed, manufactured,
and/or supplied by ANALOGIC (the “Components”) to be integrated into TOMOTHERAPY’s Product;

     WHEREAS ANALOGIC will lead and coordinate the development of the aforesaid Components;

     WHEREAS, the Parties intend that, upon the successful development of the Components,
ANALOGIC will be the exclusive manufacturer of the Components and TOMOTHERAPY will be the
exclusive seller of the Product.

     NOW, THEREFORE, in consideration of the above premises and the mutual obligations undertaken,
the parties hereto agree as follows:

1. DEVELOPMENT

	 	a.	 	Design: ANALOGIC shall design the Components in accordance with the Engineering
Requirement Specification (“SPECIFICATION”) attached as Exhibit 1, in accordance
with the Milestones attached as Exhibit 2.

 

 

Confidential
treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality
request. Omissions are designated as [  *  ]. A complete version
of this exhibit has been filed separately with the Securities and
Exchange Commission.

 

Table of Contents

Page 2

27 JANUARY 2002

	 	b.	 	Development Test Bed: ANALOGIC shall provide to TOMOTHERAPY one (1)
prototype of the Components. Each party shall perform all tests required of it
respectively, by the “Prototype Testing” section of the Development Plan as set forth in
the SPECIFICATION and the prototype will be suitable for regulatory testing.
	 
	 	c.	 	First (1st) Pilot Production Components: In accordance with Milestones
ANALOGIC shall produce and deliver to TOMOTHERAPY three (3) 1st pilot
production Components which meet the criteria specified in the SPECIFICATION.
Each party shall perform all tests required of it as set forth in the SPECIFICATION.
TOMOTHERAPY may request changes to the design of the 1st pilot production
Components in accordance with Section l(g), below. Certain components of the 1st
pilot production Components such as the BCS, DCS, RCS, DAS, and cabling will not
have been manufactured per the cGMP/QSR guidelines. The components of the
Components which do not meet these guidelines will have to be exchanged,
remanufactured, or brought into compliance by other means prior to shipment to an end
user. The methodology, documentation, and costs of how this will be accomplished
will be mutually agreed upon on a component by component basis.
	 
	 	d.	 	Second (2nd) Pilot Production Components: In accordance with Milestones and any
modifications or changes to the SPECIFICATION requested by TOMOTHERAPY and
agreed to by ANALOGIC, ANALOGIC shall produce and deliver to
TOMOTHERAPY six (6) 2nd pilot production units of the Components which
incorporate any such changes to the prototype or the 1st pilot production Components,
and meet the SPECIFICATION. ANALOGIC shall perform all tests required to meet
the SPECIFICATIONS. TOMOTHERAPY may request changes to the design of pilot
production Components in accordance with Section l(g), below. With the shipment of
any 2nd pilot production Components (assuming the design has been frozen and the
final documentation has been completed) and all future Components to
TOMOTHERAPY, ANALOGIC will provide to TOMOTHERAPY a technical file
which meets the requirements of cGMP/QSR and/or CE MDD.
	 
	 	e.	 	NRE: TOMOTHERAPY will pay ANALOGIC for the Non-Recurring Engineering
(“NRE”) in accordance with the agreed milestones attached as Exhibit 2.
	 
	 	f.	 	Manufacturing: The Components with the exception of 1.c will be manufactured by
ANALOGIC so as to qualify and validate all manufacturing processes in accordance
with the Good Manufacturing Practices and the Quality System Regulation
promulgated by the United States Food and Drug Administration (“FDA”) and
International Standards Organization’s ISO 9001.
	 
	 	 	 	For a period commencing with the shipment to a clinical user (in this Agreement,
“clinical user” includes TOMOTHERAPY’s Centers of
Excellence institutions) of the first pilot
production HI-ART II meeting SPECIFICATIONS and continuing for a period of four and one half
years thereafter, ANALOGIC will be the exclusive manufacturer of the Components, provided
however, that ANALOGIC’S manufacturing exclusivity for tables
only applies to the [  *  ] units ordered

 

Table of Contents

Page 3

27 JANUARY 2002

	 	 	 	by TOMOTHERAPY. After the first [  *  ]
tables are purchased by TOMOTHERAPY,
TOMOTHERAPY may procure or manufacture another table. However, it is understood by the Parties
that ANALOGIC owns all rights to its table design. Similarly, after the 4 and one half year
manufacturing exclusivity for the Components, TOMOTHERAPY may procure or manufacture the
Components of another design. It being understood by the Parties that ANALOGIC owns all rights
to its Components design.
	 
	 	g.	 	Engineering Changes: ANALOGIC shall transmit to TOMOTHERAPY for approval all proposed
Engineering Change Orders (ECO) that have, or could potentially have, an impact on the form,
fit, function, SPECIFICATIONS or regulatory approvals of the Components. Specifically in
regard to the impact on regulatory approvals, all ECO’s relating to those ANALOGIC Components
which are called out in TOMOTHERAPY’S standards construction file shall be transmitted to and
approved by TOMOTHERAPY. TOMOTHERAPY is responsible for insuring that ANALOGIC has an updated
list of relevant Components, which are listed, in TOMOTHERAPY’S standard construction file.
TOMOTHERAPY must respond within 48 hours after receiving all ECO information. ECO’s which do
not effect fit, form or function will not require approval by TOMOTHERAPY. TOMOTHERAPY will
not need to approve any ECO which is required by regulatory authority. These requirements
shall remain in effect throughout the production phase of this Agreement. If TOMOTHERAPY
desires to make a change to the SPECIFICATION for the Components at any time, it will make a
written request for change to ANALOGIC and ANALOGIC will respond in writing as to the
effect(s) of the change (“Change Implications”), if any, including without limitation, the
Components availability, Components price, and NRE. ANALOGIC will not be obliged to proceed
with making any requested changes unless the parties above first agree to the change
implications in writing. ANALOGIC will provide copies of all final Engineering Changes Orders
that are required by regulatory authority, that impact any ANALOGIC Component listed in the
standards construction file, or those requested by TOMOTHERAPY. These copies will include the
cover page and excerpts that sufficiently describe the change.
	 
	 	h.	 	Records; Regulatory Approval:

	 	i.	 	During the term of this Agreement, ANALOGIC shall keep detailed records of
all materials, processes, designs, protocols, and tests relevant to the Components and
all information required by the United States Food and Drug Administration (“FDA”) for
approval of the manufacturing and marketing of the Components that are not explicitly
the responsibility of TOMOTHERAPY under this Agreement. However, certain components of
the 1st pilot production as described in section l.c may not follow cGMP and
will be brought into compliance by an agreed method on a component by component basis.
ANALOGIC shall submit copies of such records to TOMOTHERAPY upon TOMOTHERAPY’S request.
TOMOTHERAPY will be responsible for filing

 

Table of Contents

Page 4

27 JANUARY 2002

	 	 	 	with the FDA and obtaining all other necessary regulatory approvals to market and sell
the System.
	 
	 	ii.	 	ANALOGIC hereby agrees to make available to TOMOTHERAPY all technical information within its
control with respect to the Components and ANALOGIC’s operations that is required by
regulatory clearances such as the United States Food and Drug Administration to obtain 510(k)
approval and required by a notified body to obtain the CE mark. TOMOTHERAPY shall treat all
such information as Confidential Information in accordance with Section 16 of this Agreement.
	 
	 	iii.	 	In the event that any component or any of the Components
designed or manufactured by ANALOGIC of the Product are recalled by TOMOTHERAPY or ANALOGIC solely as the
result of (A) ANALOGIC’s gross negligence or willful misconduct, (B) the recalled Component’s
failure to meet the SPECIFICATIONS, (C) ANALOGIC’s failure to comply with Quality System
Regulation, Good Manufacturing Practices, or ISO 9001,or (D) any other material
breach of this Agreement by ANALOGIC, ANALOGIC at its option shall either: provide replacement
parts to TOMOTHERAPY as soon as is reasonably possible or accept the return of the affected
units from TOMOTHERAPY for repair by ANALOGIC. The Parties will cooperate fully with each other
(including obtaining advance approval of all recall-related expenses to be paid by ANALOGIC,
which approval shall not be unreasonably withheld) in effecting any recall of the Components
and communicating with purchasers, users and the media. ANALOGIC shall not be responsible for
any recall related expenses arising from any other recall, including incompatibility of the
Components with any other part of the System unless such compatibility is required
in the Specifications. If any recall or other event requiring corrective action occurs for any
reason, than those set forth in the first sentence of this paragraph (iii)’s including due to
(AA) use of any TOMOTHERAPY products or software in combination with the Components (where the
combination itself gives rise to the recall and not the Components alone), (BB) modification of
the ANALOGIC software by any party (including TOMOTHERAPY) other than ANALOGIC, or (CC) any
other act or omission on TOMOTHERAPY’S part, then all costs and expenses associated with the
recall or other event, including the cost of replacement parts and/or return and repair of the
affected units, shall be borne solely by TOMOTHERAPY.
	 
	 	iv.	 	ANALOGIC will notify TOMOTHERAPY immediately of any Quality System Regulation audit of
ANALOGIC by the United States Food and Drug Administration or other inspection of ANALOGIC’s
records or its facilities by any federal, state regulatory agency as well as the results of
such audit or inspection.
	 
	 	v.	 	TOMOTHERAPY shall have the right to conduct an appropriate audit of ANALOGIC’s relevant
records and operations to evaluate compliance to the applicable sections of the cGMPs- QSR,
and ISO 9001. Such audits will be at a date acceptable to both ANALOGIC and TOMOTHERAPY and
will be

 

Table of Contents

Page 5

27 JANUARY 2002

conducted during ANALOGIC’s normal business hours. Within ten (10) days after
each such audit, TOMOTHERAPY will provide written notification of any non-compliance
issues. If ANALOGIC concurs with such conclusions (concurrence will not unreasonably
be withheld), it agrees to use commercially reasonable efforts to be in compliance
within 60 days following such written notification.

2. OWNERSHIP OF INTELLECTUAL PROPERTY

	 	a.	 	In performing the Development Work, ANALOGIC will utilize systems, sub-systems,
parts, software, know-how, and other intellectual and physical property that it owned
and/or had in its possession prior to the commencement of the Development Work (“ANALOGIC
Information”). Similarly, TOMOTHERAPY may utilize systems, subsystems, parts, software,
know-how, and other intellectual and physical property that it owned and/or had in its
possession prior to the commencement of the Development Work (“TOMOTHERAPY Information”).
With respect to ANALOGIC Information and TOMOTHERAPY Information, the Parties agree as
follows:

	 	i.	 	ANALOGIC owns the Proprietary Technology embedded
in the ANALOGIC Information and any improvements to it developed by
ANALOGIC during the course of the Development Work.
	 
	 	ii.	 	TOMOTHERAPY owns the Proprietary Technology embedded in the
TOMOTHERAPY Information and any improvements to it developed by TOMOTHERAPY
during the course of the Development Work.
	 
	 	iii.	 	To the extent that ANALOGIC develops Proprietary Technology
	 
	 	 	 	improvements to TOMOTHERAPY Information during the course of performing the
Development Work, and except as provided in Section 13.d. below, ANALOGIC owns
the improvements (but not the underlying TOMOTHERAPY Information) and grants
TOMOTHERAPY a license to use, modify, market and sublicense the ANALOGIC
improvements to the TOMOTHERAPY Information, and TOMOTHERAPY may assign the same
to a third party but only with ANALOGIC’s consent which consent will
not be unreasonably withheld, except that TOMOTHERAPY may assign the same
without ANALOGIC’s consent in connection with the assignment this Agreement
pursuant to Section 24 of this Agreement.
	 
	 	iv.	 	To the extent that TOMOTHERAPY develops Proprietary Technology
improvements to ANALOGIC Information during the course of performing the
Development Work, TOMOTHERAPY owns the improvements (but not the underlying
ANALOGIC Information) and grants ANALOGIC a license to use, modify, market and
sublicense the TOMOTHERAPY improvements to the ANALOGIC Information, and
ANALOGIC may

 

Table of Contents

Page 6

27 JANUARY 2002

	 	 	 	assign the same to a third party but only with TOMOTHERAPY’s consent which consent will
not be unreasonably withheld.
	 
	 	v.	 	Either Party may develop new Proprietary Technology during the course of the Development
Work that is embedded in the Components and that is not an improvement to the Information of
the-Party (as covered in subsections 2 a. iii and iv above) (“Development Information”). The
Party that created the Development Information owns the Development Information, and may use,
modify, market, sublicense, and transfer such Development Information for any purpose other
than for Radiation Therapy Delivery (as defined below), and may use, modify, market,
sublicense, and transfer the Development Information for Radiation Therapy Delivery only with
the written consent of the other Party, which consent may not be unreasonably withheld,
subject however to the rights of TOMOTHERAPY set forth in the final sentence of this
paragraph. The owner of the Development Information hereby grants to the other Party a license
to use, modify, market, and sublicense the Development Information, and may
transfer such license, for any purpose other than for Radiation Therapy Delivery (as defined
below), and such licensee may use, modify, market, sublicense, and transfer the license to the
Development Information for Radiation Therapy Delivery only with the written consent of the
other Party, which consent may not be unreasonably withheld, subject however to the rights of
TOMOTHERAPY set forth in the final sentence of this paragraph. For purposes of this Agreement,
“Radiation Therapy Delivery” means any system delivering external beam radiation in a medical
context, and does not include radiation therapy planning. Notwithstanding the foregoing,
TOMOTHERAPY may use, modify, market, and sublicense all Development Information in connection
with the development, manufacture and sale of its Product without the consent of ANALOGIC, and
may assign its own Development Information and its license to Development Information owned by
ANALOGIC without ANALOGIC’s consent in connection with the sale or transfer of substantially
all of its assets in a transaction to which the provisions of Section 24 of this Agreement
apply, provided that in conjunction with the sale or transfer of TOMOTHERAPY’S assets to a
third party, that the third party agrees to be bound by all of the terms of this Agreement, as
set forth in Section 24 of this Agreement for Analogic to manufacture and supply to the
receiver of the assets all of the Components which are the subject of this agreement
manufactured or supplied by ANALOGIC.
	 
	 	vi.	 	Development Information, that is jointly created by the Parties shall be treated as
separately owned by each Party, but each Party’s interest shall be subject to the rights and
restrictions imposed by the preceding paragraph v on separately owned=Development
Information,, without the obligation of the Parties to account to each other for or share with
the other party the proceeds arising from such jointly created Development Information.

 

Table of Contents

Page 7

27 JANUARY 2002

	 	vii.	 	Nothing herein is intended to give one Party any rights to the
Proprietary Technology of the other Party existing on the date of this
Agreement is entered into, except as is necessary to achieve the purposes of
this Agreement during the term of this Agreement and any mutually agreed upon
extensions to this Agreement.

	 	b.	 	While ANALOGIC owns the rights to the patient table pallet
design that is to
be delivered to TOMOTHERAPY pursuant to the Statement of Work and may
supply this exact table pallet to other customers, ANALOGIC acknowledges
and agrees that it will not knowingly supply this exact table pallet for use by
Third Parties in Radiation Therapy Delivery.
	 
	 	c.	 	TOMOTHERAPY acknowledges and agrees that ANALOGIC is an OEM supplier
of subassemblies, whole instruments and systems. It also acknowledges that it
understands ANALOGIC intends to continue to remain in this business and, subject
to any limitations imposed upon it hereunder, may even design and manufacture
products that contain some or all of the technology and designs used in the
Components, including, among other things, certain mechanics, circuitry and
software, proprietary to ANALOGIC. In addition, the Components may embody
certain patented features as well.

3. PURCHASE AND DELIVERY

ANALOGIC agrees to manufacture and sell the Components to TOMOTHERAPY, and TOMOTHERAPY
agrees to purchase its total number requirements of the Components exclusively from
ANALOGIC per section 1.f. and upon the following terms:

	 	a.	 	Upon TOMOTHERAPY’S acceptance of the pilot production Components, (which
acceptance shall be in accordance with the Components meeting the
SPECIFICATIONS), TOMOTHERAPY shall provide ANALOGIC with a rolling
twelve (12) month forecast of its purchase requirements for the Components, updated
on a monthly basis. The initial forecast will be accompanied by a firm purchase order
for the first six (6) months subject to the lead time defined below, and a projection of
orders for the following six (6) months. Three months thereafter, firm purchase orders
shall be furnished on the first week of each rolling month for Components to be
delivered in the third full calendar month following the month in which ANALOGIC
receives the purchase order. Projections of orders shall be for the parties’ planning
purposes only, and, except for a firm commitment to purchase Components for the next
three months, shall not constitute binding commitments upon TOMOTHERAPY.
TOMOTHERAPY may modify any purchase order up to ninety (90) days prior to the
beginning of the month covered by such purchase order. TOMOTHERAPY agrees
that for economic and production efficiency reasons ANALOGIC requires a consistent
and steady production flow (no production breaks month to month).
	 
	 	b.	 	ANALOGIC shall acknowledge promptly each TOMOTHERAPY purchase order in
writing and confirm delivery dates. Each order shall be subject to a lead-time of 120
days (“Lead Time”). TOMOTHERAPY acknowledges that some components used in

 

Table of Contents

Page 8

27 JANUARY 2002

	 	 	 	the manufacture of the Components may be designated by ANALOGIC as “Long-lead-time
Items” (“LLTI’s). ANALOGIC shall be authorized in writing by TOMOTHERAPY to place orders
for sufficient quantities of LLTI’s necessary to meet TOMOTHERAPY’S projected purchases set
forth on its forecasts. In the event that forecasted quantities of Components are not
actually ordered by TOMOTHERAPY, TOMOTHERAPY shall reimburse ANALOGIC for the LLTI’s unique
to TOMOTHERAPY’S Components purchased by ANALOGIC in connection with such forecasted
quantities which cannot be used elsewhere within ANALOGIC, or cancelled, or returned to the
vendor. The reimbursement value of such LLTI’s shall be
[  *  ]%.
	 
	 	c.	 	All sales of the Components shall be subject to the terms and conditions of this
Agreement. Except with respect to transaction-specific items such as quantities,
requested delivery dates, destinations and shipping instructions, purchase orders or
other similar documents issued by TOMOTHERAPY are for TOMOTHERAPY’S
administrative convenience only. No other terms or conditions contained in a purchase
order or such other similar document shall be of any force or effect. If there is any
conflict or difference in interpretation between such transaction specific items in a
TOMOTHERAPY purchase order and this Agreement, the terms and conditions of this
Agreement shall supersede those of such purchase order.
	 
	 	d.	 	Subject to the lead time requirements set forth herein, ANALOGIC shall be ready and
able to timely supply all quantities of Components ordered by TOMOTHERAPY that
are within its forecast and/or accepted by ANALOGIC. ANALOGIC shall not be liable
for failure or delay in filling TOMOTHERAPY orders because of any cause beyond the
control of or occurring without the fault of ANALOGIC.
	 
	 	e.	 	Should any parts or sub-components used by ANALOGIC in manufacturing the
Components either become unavailable for purchase and Analogic is advised thereof
by its supplier, or unavailable for a reasonable price, ANALOGIC shall give
TOMOTHERAPY notice thereof. Subject to such time limitations imposed on
ANALOGIC by the component manufacturer(s) or distributor(s), as the case may be,
during which ANALOGIC can acquire such components, TOMOTHERAPY may
exercise last time buy rights for the 

component(s) by authorizing ANALOGIC to place
purchase orders within the 30 days following such notice from ANALOGIC to
TOMOTHERAPY. The cost of the unique Components (components which are
purchased specifically for TOMOTHERAPY’S Product) which cannot be used
elsewhere within ANALOGIC purchased pursuant to the last time buy shall be paid for
in full by TOMOTHERAPY and maintained as dedicated inventory owned by
TOMOTHERAPY and TOMOTHERAPY will receive a corresponding credit when the
component is used in the Components by reducing the Components price
by [  *  ]%. Alternatively, Analogic may agree to
redesign the relevant component or components for a mutually agreed upon price.

4. PRICES, ADJUSTMENTS, AND PAYMENTS

	 	a.	 	The price to be paid by TOMOTHERAPY to ANALOGIC for the
Components is set forth on Exhibit 3 hereto. These initial
prices shall be valid for a period of two years

 

Table of Contents

Page 9

27 JANUARY 2002

	 	 	 	following shipment to a clinical user of the first production HI-ART II (system #11)
meeting SPECIFICATIONS. Thereafter, beginning on the second anniversary of the shipment to
a clinical user of the first production HI-ART II meeting SPECIFICATIONS, and every [  *  ] thereafter, the Parties shall review prices and quantities with the understanding
that prices may be adjusted by mutual agreement in response to the world market for
components, production yield, cost improvement, and other factors deemed relevant by the
parties. If parties cannot reach a mutual agreement, the parties will follow the
arbitration process outlined in section 23 hereafter. Unless otherwise specified or
required by law, all prices will be quoted and billed exclusive of federal, state or local
excise, sales or other similar taxes. Such taxes, when applicable, will appear as
additional items on invoices.
	 
	 	b.	 	ANALOGIC agrees that the price for the Components is at least as favorable to
TOMOTHERAPY as the price and the terms upon which ANALOGIC sells
comparable CT components to any other customer under similar circumstances.
	 
	 	c.	 	Terms of payment are net 30 days from of the date of delivery or invoice; whichever
is later, for shipments made.

5. SHIPMENTS OF PRODUCT

ANALOGIC shall ship the Products Ex Works (Incoterms 2000), ANALOGIC’s Peabody, MA plant via
carriers designated by TOMOTHERAPY.

6. TERM CHANGE

This Agreement will begin on the Effective Date and will continue for an initial term (“Initial
Term”) of four and one half (4.5) years from the shipment to a clinical user of the first pilot
production HI-ART II meeting SPECIFICATIONS, unless earlier terminated pursuant to Section 7 below.
If no notice of termination is given at least six (6) months prior to expiration of the Initial
Term, then this Agreement shall continue in effect until terminated by either party upon six (6)
months written notice thereafter.

7. TERMINATION

	 	a.	 	In the event of a substantial or material breach of any term or condition of this
Agreement by either party, which shall include, but not be limited to, non-payment of
invoices when due which breach is not or cannot be corrected by the breaching party within
thirty (30) days after notice (unless a longer time is expressly provided for herein), this
Agreement may be terminated by the other party by giving notice of termination, to take
effect forthwith upon the giving of such notice. Notwithstanding the foregoing,
TOMOTHERAPY may terminate this Agreement with respect to an unexcused ANALOGIC breach
related to failure to timely deliver Components only if ANALOGIC fails to deliver ordered
Components within sixty (60) days of the scheduled delivery date specified in any
TOMOTHERAPY purchase order that complies with TOMOTHERAPY’S forecast and has been accepted
by ANALOGLC. Additionally, a force majeure would be deemed an excused ANALOGIC breach.

 

Table of Contents

Page 10

27 JANUARY 2002

	 	b.	 	This Agreement may be terminated immediately by the either party without the
requirement of prior notice if the other party suspends operations, files or suffers to be
filed against it a petition in bankruptcy, or the like, executes an assignment for the
benefit of creditors, or is adjudicated as bankrupt by a court of competent jurisdiction.

8. PRODUCT CHANGES

ANALOGIC shall notify TOMOTHERAPY in writing of any change to the Components which do affect the
Component’s form, fit, function, SPECIFICATIONS or regulatory compliance. ANALOGIC shall not make
any change to the SPECIFICATIONS or to the Component’s labeling without TOMOTHERAPY’S prior written
consent, which consent will not be unreasonably withheld.

9. QUALITY CONTROL

	 	a.	 	ANALOGIC shall perform incoming inspection and testing on all materials it receives
from any source for inclusion in any of the Components in accordance with ANALOGIC’s
Corporate Quality Assurance Procedure Sampling Inspection/Testing by Attributes Procedure,
as amended from time to time in the normal course of business. In no case shall
non-conforming materials which affect the Component’s form, fit, or function be used in the
manufacture of the Components.
	 
	 	b.	 	The Components will be designed and manufactured by ANALOGIC in a manner that
will qualify and validate all manufacturing processes in accordance with current Good
Manufacturing Practices and the Quality System Regulations promulgated by the United States
Food and Drug Administration (“FDA”) and ISO 9001 and for
the Components after July 2002.
	 
	 	c.	 	All the Components shall meet the SPECIFICATIONS and shall be subjected to
ANALOGIC’s quality control systems and standards, which at all times will comply
with applicable regulatory requirements. ANALOGIC shall permit TOMOTHERAPY
to review periodically ANALOGIC’s relevant production and quality control
procedures and records and to visit ANALOGIC’s facilities at reasonable times with a
representative of ANALOGIC present.

10. OUTGOING INSPECTION AND PERFORMANCE INDICATORS

	 	a.	 	Beginning with the first pilot production Components, ANALOGIC will inspect all
outgoing Components to be supplied to TOMOTHERAPY to be strictly in
accordance with SPECIFICATIONS and perform outgoing acceptance testing.
TOMOTHERAPY will monitor the delivery and quality performance of ANALOGIC.
	 
	 	b.	 	An overview or SCAR (Supplier Corrective Action Request) will be generated by
TOMOTHERAPY on a quarterly basis or more frequently if necessary. The
performance indicators to be applied shall cover:

 

Table of Contents

Page 11

27 JANUARY 2002

% Complete and On-time delivery

Failures per unit (normalized over total quantity consumed monthly)

Failure symptoms, documentation deficiencies, packaging quality.

ANALOGIC will be responsible to provide a written quality report within fifteen (15)
days from receipt of TOMOTHERAPY’s SCAR quality report that contains corrective
actions to remedy failures.

ANALOGIC will be responsible to provide a written quarterly quality report to be issued by the
first Friday of each month that provides all key performance indicators as mutually agreed to with
TOMOTHERAPY.

11. SERVICE AND SPARE PARTS

	 	a.	 	ANALOGIC will provide Parts for a period of
seven (7) years following the last serial
delivery of the Components under this Agreement. The price of the Parts will be that
listed in Exhibit 4, SPARE PARTS PRICE LIST (Which will be determined by the
parties in good faith based on their prior practices, and otherwise based on industry
standards). In the event that a Part becomes obsolete, ANALOGIC will provide
TOMOTHERAPY notice as soon as ANALOGIC becomes aware of the anticipated
obsolescence and offer TOMOTHERAPY the opportunity to make a last buy. In the
event that ANALOGIC learns that a component used in manufacturing a Part of the
Components will become obsolete, it will notify TOMOTHERAPY and
TOMOTHERAPY may request ANALOGIC, at TOMOTHERAPY’s expense, to re-engineer the Part using components that are not obsolete.
	 
	 	b.	 	TOMOTHERAPY will provide ANALOGIC with Forecasts for Parts. On the 15th of
each month, TOMOTHERAPY will provide ANALOGIC a twelve (12) month
Forecast of its Parts needs. The first three (3) months of the Parts Forecast consists a
firm and binding commitment to purchase the Parts. ANALOGIC will not be
obligated to deliver parts in excess of thirty (30) percent above the second three (3)
months Parts Forecast.
	 
	 	d.	 	ANALOGIC will provide a quotation for Parts within five (5) business days if
TOMOTHERAPY seeks to purchase Parts not included in its Forecast and not in stock
at ANALOGIC.
	 
	 	e.	 	ANALOGIC will provide TOMOTHERAPY a list of all Parts that are Field
Replacement Units (“FRU”). This list will contain the following information: (1)
ANALOGIC part number; (2) ANALOGIC part description; (3) Price of new FRU;
(4) FRU lead-time and (5) List of repairable and non-repairable FRUs; (6) Price for
non-warranty repairable FRU’s.
	 
	 	f.	 	TOMOTHERAPY may return to ANALOGIC Parts, which are identified as repairable
for warranty and out-of-warranty repairs. ANALOGIC will repair the Parts described
in this sub-paragraph to the minimum allowable revision level within
a targeted thirty (30) to forty-five (45) working day period from
receipt of the returned Parts.

 

Table of Contents

Page 12

27 JANUARY 2002

	 	g.	 	ANALOGIC will provide repair services for the Components and Parts for a period of
seven years following the last serial delivery of the Components pursuant to this
Agreement.

12. WARRANTY AND REPAIRS

	 	a.	 	Except for Software, which is defined and provided for in Section 13, ANALOGIC
warrants to TOMOTHERAPY that all of the Components sold to TOMOTHERAPY
under this Agreement will be at the time of their delivery, free from defects in
workmanship and material and in compliance with the Specifications. ANALOGIC
further warrants that all of the Components sold to TOMOTHERAPY under this
Agreement will, on the date of shipment by ANALOGIC, have been manufactured by
ANALOGIC in accordance with the FDA’s current Good Manufacturing Practices,
Quality System Regulations, ISO 9001.
	 
	 	b.	 	The warranty period for the Components shall be twelve (12)
months from the date of
shipment by TOMOTHERAPY to a customer of a System into which the Components
have been integrated or fifteen (15) months from the date of shipment of the
Components by ANALOGIC to TOMOTHERAPY, whichever period occurs earlier.
ANALOGIC will, at its option, repair or replace defective Components returned
during the warranty period at no cost to TOMOTHERAPY, provided that each Party is
responsible for the shipping cost of the Components it sends to the other.
	 
	 	c.	 	ANALOGIC shall perform an inspection and test of field-returnable Components to
confirm that there is a defect requiring warranty repair or replacement. Returned
Components found not to be defective or no longer under warranty shall be repaired at
TOMOTHERAPY’s expense at ANALOGIC’s then current standard rates for out of
warranty repairs.
	 
	 	 	 	These warranties are made upon the express condition that:

	 	i.	 	ANALOGIC is given prompt notice upon discovery by
TOMOTHERAPY of such nonconformity, with an explanation of the alleged
deficiencies.
	 
	 	ii.	 	Such Product is returned to ANALOGIC at the expense of
TOMOTHERAPY after receipt of a Return Authorization (RA) from ANALOGIC. Upon
their repair or replacement, they shall be returned to TOMOTHERAPY as
directed, at the expense of ANALOGIC.
	 
	 	iii.	 	Examination of such Components by ANALOGIC discloses
that the nonconformity actually exists and was not caused by accident,
misuse, neglect, alteration, improper installation or use, improper repair
or improper testing; and
	 
	 	iv.	 	Such Components (including the Software, as defined
below) have not been modified, altered or changed by any person other than
ANALOGIC or its duly authorized repair agents, and other than modifications
by TOMOTHERAPY as provided under Section 13 a. iii. of this Agreement.

 

Table of Contents

Page 13

27 JANUARY 2002

THESE WARRANTIES ARE IN LIEU OF AND EXCLUDE ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, ORAL
OR WRITTEN, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY AND/OR FITNESS FOR A
PARTICULAR PURPOSE. THE OBLIGATION TO REPLACE OR REPAIR IS THE SOLE REMEDY FOR BREACH OF
WARRANTY. ANALOGIC WILL NOT IN ANY EVENT BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER. ANALOGIC WILL NOT BE LIABLE FOR ANY LOST PROFITS
OR DAMAGES FROM LOSS OF USE, OR LOST DATA, EVEN IF ANALOGIC HAS BEEN ADVISED, KNEW OR SHOULD
HAVE KNOWN OF THE POSSIBILITY THEREOF. IN NO EVENT SHALL THE RESPONSIBILITY AND LIABILITY OF
ANALOGIC IN CONNECTION WITH ANY OF THE COMPONENTS BE GREATER THAN THE PRICE PAID BY TOMOTHERAPY
FOR THE NON-CONFORMING PORTION OF THE COMPONENTS. TOMOTHERAPY ACKNOWLEDGES THAT IT’S EXCLUSIVE
REMEDIES SET FORTH HEREIN ALLOCATE RISKS BETWEEN THE PARTIES FAIRLY AND IN A MANNER WHICH UNDER
NO CIRCUMSTANCES WILL CAUSE SUCH REMEDIES TO FAIL OF THEIR ESSENTIAL PURPOSE.

13. SOFTWARE LICENSE AND WARRANTY

	 	a.	 	Components may contain pre-existing ANALOGIC proprietary software
(“ANALOGIC proprietary software”) and software licensed to ANALOGIC by independent third
parties (ANALOGIC licensed “Third Party Software”). TOMOTHERAPY also may add TOMOTHERAPY
Software to the Components and/or to the System(s) into which the Components are integrated
that may be its own proprietary software or other software licensed by TOMOTHERAPY directly
from other third parties (collectively, TOMOTHERAPY Software). ANALOGIC proprietary Software
and ANALOGIC licensed Third-Party Software are sometimes referred to collectively herein as
the “ANALOGIC Software.” ANALOGIC hereby grants to TOMOTHERAPY for the term of this
Agreement, subject to the conditions set forth herein, a non-exclusive, non-transferable
(except as provided in Section 24 of this Agreement) worldwide license:

	 	i.	 	to market and sublicense the ANALOGIC Software in
object code form only;
	 
	 	ii.	 	to use internally the ANALOGIC proprietary Software
in source code form, solely for the purposes of understanding the operation
of the Product, supporting TOMOTHERAPY’s installed Product base, and
accomplishing the purposes of clause (iii) below; and
	 
	 	iii.	 	to make modifications and improvements to the
ANALOGIC proprietary Software for distribution per clause (i)
above.

Neither TOMOTHERAPY nor any of its sub-licensees shall be permitted to transfer the ANALOGIC
Software in any form except in connection with the sale of a HI-ART II System, or as
provided in Section 24 of this Agreement.

 

Table of Contents

Page 14

27 JANUARY 2002

	 	b.	 	During the term of this Agreement, TOMOTHERAPY may sublicense its distributors
to distribute and sub-license the ANALOGIC Software solely in connection with
Customers’ use of the Components which are part of a System purchased by the
customer.
	 
	 	c.	 	TOMOTHERAPY expressly acknowledges that this Agreement does not grant
TOMOTHERAPY the right to copy, reproduce, or transmit in any form the
ANALOGIC Software or any part thereof, or to authorize or permit others to do so,
except as expressly provided herein. TOMOTHERAPY shall not reverse engineer,
decompile or disassemble the ANALOGIC Software not provided hereunder in source
code form.
	 
	 	d.	 	Except as expressly provided herein, all right, title and interest in and to the
ANALOGIC Software shall at all times remain and vest solely with ANALOGIC and
its suppliers. TOMOTHERAPY shall have no access to or rights in the ANALOGIC
licensed Third-Party Software in source code form. Except with respect to
TOMOTHERAPY Software, TOMOTHERAPY agrees that it will not claim or assert
title to the ANALOGIC Software, or attempt to transfer any title thereto to any third
party. This does not apply to software developed specifically for TOMOTHERAPY,
that does not interface directly with hardware that is supplied by ANALOGIC. For
example, software developed under this contract that implements the general machine
control scheme as defined by TOMOTHERAPY, or interfaces with standard 3rd-party
components not supplied by ANALOGIC, shall be owned by TOMOTHERAPY.
	 
	 	e.	 	In the event ANALOGIC changes hardware of the Components for whatever reason the
firmware should continue to function to SPECIFICATIONS.
	 
	 	f.	 	TOMOTHERAPY’s SOLE AND EXCLUSIVE REMEDY AND ANALOGIC’S SOLE LIABILITY HEREUNDER SHALL BE TO
REPLACE ANALOGIC SOFTWARE THAT DOES NOT MEET ANALOGIC’S LIMITED WARRANTY AS SOON AS IS
REASONABLY PRACTICABLE, AND, IF REASONABLY POSSIBLE, TO MAKE THE REPLACEMENT SOFTWARE
AVAILABLE TO TOMOTHERAPY VIA SECURE DOWNLOADING OVER THE INTERNET OR BY OTHER ELECTRONIC
MEDIUM AGREEABLE TO THE PARTIES. THIS SOFTWARE WARRANTY IS IN LIEU OF AND EXCLUDES ALL OTHER
WARRANTIES, EXPRESS OR IMPLIED, ORAL OR WRITTEN, INCLUDING WITHOUT LIMITATION WARRANTIES OF
MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE. ANALOGIC WILL NOT IN ANY EVENT BE
LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER.
TOMOTHERAPY ACKNOWLEDGES THAT IT’S EXCLUSIVE REMEDIES SET FORTH HEREIN ALLOCATE RISKS BETWEEN
THE PARTIES FAIRLY AND IN A MANNER WHICH UNDER NO CIRCUMSTANCES WILL CAUSE SUCH REMEDIES TO FAIL OF THEIR ESSENTIAL PURPOSE.

 

Table of Contents

Page 15

27 JANUARY 2002

	 	g.	 	ANALOGIC SHALL HAVE NO LIABILITY OR RESPONSIBILITY FOR ANALOGIC SOFTWARE ALTERED OR
MODIFIED BY TOMOTHERAPY WITHOUT ANALOGIC’S PERMISSION OR A THIRD PARTY OR FOR DAMAGES
RESULTING FROM ACCIDENT, ABUSE, OR MISAPPLICATION OR FOR PROBLEMS DUE IN WHOLE OR IN PART
TO THE USE OR MALFUNCTION OF ANY EQUIPMENT, SOFTWARE OR ACCESSORIES NOT SUPPLIED BY
ANALOGIC OR THE INCOMPATIBILITY THEREOF WITH ANALOGIC SOFTWARE.
	 
	 	h.	 	The Software and documentation is provided with restricted rights. Use,
duplication, or disclosure by TOMOTHERAPY is subject to restrictions as set forth in FAR
Section 52.227-14 (Alternate III) or subparagraph (c)(l)(ii) of the clause at DFAR
252.227-7013, Rights in Technical Data and Computer Software. Contractor/manufacturer is
ANALOGIC Corporation, 8 Centennial Drive, Peabody, Massachusetts 01960.

14. PRODUCT LIABILITY/ INDEMNIFICATION

	 	a.	 	Notwithstanding any other provisions hereof, each Party agrees to indemnify the other,
its officers, agents, servants and employees against claims, damages, demands, suits,
actions, judgments, liabilities, defaults, or costs and expenses, including attorneys’
fees, arising from claims made against or liability imposed upon the other, by a court of
competent jurisdiction as a result of claims alleging personal injury, disability, death or
property damage, or any form or type or wrongdoing or loss arising from such
indemnifying Party’s failure to perform its respective obligations hereunder, as well as,
in TOMOTHERAPY’s case, its obligations implicitly arising out of or in connection
with the sale and/or transfer of the System, including without limitation,
TOMOTHERAPY’s burden of Customer training, service and support, its
representations made in the course of reselling or distributing the System, and its
distribution of related materials and literature. This indemnification shall be limited to
the sum of $[  *  ] in any 12-month period commencing on August 1st of any
year.
	 
	 	b.	 	Each Party hereto agrees that it will maintain product liability insurance adequate to
fulfil the indemnification obligation hereunder in each such 12-month period
commencing on August 1st of each year.
	 
	 	c.	 	In the event that a claim is made against a Party seeking indemnification, that Party
shall promptly notify the other Party of the claim, allow the other Party to defend it in
the name of such Party and to fully cooperate with its insurers, if relevant, and its
counsel in the defense against the claim.

15. PATENTS/INDEMNIFICATIONS

	 	a.	 	ANALOGIC will defend TOMOTHERAPY at ANALOGIC’s cost and expense, including reasonable
attorneys’ fees, against any claim of infringement of a United States, Canadian, or
European Union patent brought against TOMOTHERAPY to the extent that such a claim pertains
to Components designed by ANALOGIC, provided

 

Table of Contents

Page 16

27 JANUARY 2002

	 	 	 	that TOMOTHERAPY gives ANALOGIC prompt written notice of such claim and the right to
maintain sole control of the defense and all negotiations for settlement of such claim. If
a final injunction is obtained against TOMOTHERAPY’S use of Components because of
infringement of third Party intellectual property, ANALOGIC will, at ANALOGIC’s option and
at ANALOGIC’s expense, either procure for TOMOTHERAPY the right to continue using the
Components, replace or modify the Components so that the Components become non-infringing,
or grant TOMOTHERAPY credit for the purchase price less reasonable depreciation of
infringing Components and accept the return of Components sold by ANALOGIC to TOMOTHERAPY.
Under the terms of this Agreement, ANALOGIC will not accept any liability, nor hold any
person harmless from infringement claims relating to: (i) Components supplied by ANALOGIC
containing components which have been manufactured or produced by others and which carry
the original manufacturer’s patent indemnifications; (ii) Components purchased hereunder
but altered by TOMOTHERAPY or others (excluding ANALOGIC and ANALOGIC’s authorized agents)
to infringe such patent; and (iii) a combination of Components and other equipment;
provided, however, that ANALOGIC shall defend such claim to the extent that such
infringement claim would lie against the Product notwithstanding such alteration or
combination.
	 
	 	b.	 	Notwithstanding anything to the contrary in this Agreement, if any alleged
infringement of a United States, Canadian, or European Union patent by Components
arisen from designs developed and supplied by TOMOTHERAPY, then ANALOGIC
shall not be required to repair or replace the Components at ANALOGIC’s cost or in
any way indemnify TOMOTHERAPY as set forth in this Agreement.
	 
	 	c.	 	TOMOTHERAPY agrees to defend ANALOGIC at TOMOTHERAPY’s cost and
expense, including reasonable attorneys’ fees, against any claim of patent infringement
by reason of use by Analogic of TOMOTHERAPY’s specifications, intellectual
property, or other information in the Components. TOMOTHERAPY shall indemnify
and hold ANALOGIC harmless against any loss, damage and cost reasonably incurred
by ANALOGIC arising out of or related to such infringement claim.
TOMOTHERAPY’s obligations with respect to such infringement claims are expressly
conditioned upon ANALOGIC giving TOMOTHERAPY prompt notice of such
infringement claim and granting TOMOTHERAPY in writing exclusive control over
ANALOGIC’s defense or settlement and cooperating with TOMOTHERAPY at
TOMOTHERAPY’s expense.

16. CONFIDENTIALITY

The Mutual Non-Disclosure agreement (NDA) signed by the Parties on February 15, 2001, shall
apply during the term of this agreement.

17. COMPLIANCE WITH LAWS

ANALOGIC and TOMOTHERAPY, respectively, represent that they are and will remain in compliance with
all applicable laws, rules, regulations, ordinances, judgments, decrees, orders,

 

Table of Contents

Page 17

27 JANUARY 2002

writs and injunctions of all United States government agencies and all foreign governments and
agencies thereof that affect their business, properties or assets.

18. ENTIRE AGREEMENT; NO WAIVER

This Agreement and the Development and Manufacturing Agreement signed October 9 2001, contain the
entire agreement between the parties relating to TOMOTHERAPY’s purchase of the Components from
ANALOGIC. If a conflict develops, this Development and OEM Supply Agreement shall govern. None of
the terms of this Agreement shall be deemed to be waived or amended by either Party unless such
waiver or amendment specifically references this Agreement and is in writing signed by the Party to
be bound. Waiver by either Party of any default by the other will not be deemed a waiver by such
Party of any default by the other that may thereafter occur.

19. FORCE MAJEURE

If performance of this Agreement by ANALOGIC or TOMOTHERAPY is prevented or delayed by reason of
any cause beyond the control of, and without the fault of, the Party affected, except the
obligation to make payment for Components purchased, and which cannot be overcome by commercially
reasonable diligence (including, without limitation, acts of nature, strikes, energy or materials
shortages or obsolescence, acts of civil or military authority (including changes in government
laws and regulations), fires, floods, epidemics, wars and riots), the Party affected shall be
excused from such performance to the extent that it is necessarily prevented or delayed thereby,
during the continuance of any such happening or event, and this Agreement shall be deemed suspended
so long as and to the extent that any such cause prevents or delays its performance. In order to
obtain a suspension under this provision, the Party invoking Force Majeure shall send written
notice thereof to the other Party within a reasonable time after the invoking party knows that
performance would be delayed or prevented due to the Force Majeure in question.

21. LIMITATION OF LIABILITY

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR ANTICIPATED PROFITS, INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES WITH
RESPECT TO ANY CLAIM ARISING OUT OF THIS AGREEMENT OR ANY PERFORMANCE HEREUNDER, WHETHER SUCH CLAIM
SOUNDS IN TORT, CONTRACT, BREACH OF WARRANTY OR ANY OTHER THEORY. THE REMEDIES GRANTED TO EACH
PARTY HEREIN ARE SOLE AND EXCLUSIVE. EACH PARTY ACKNOWLEDGES THAT IT’S EXCLUSIVE REMEDIES SET FORTH
HEREIN ALLOCATE RISKS BETWEEN THE PARTIES FAIRLY AND IN A MANNER WHICH UNDER NO CIRCUMSTANCES WILL
CAUSE SUCH REMEDIES TO FAIL OF THEIR ESSENTIAL PURPOSE.

22. NOTICES

All notices given under this Agreement shall be in writing and may be delivered (i) by hand,
(ii) by United States mail, certified or registered, return-receipt requested, (iii) by overnight-courier service, or (iv) by facsimile transmission if followed by overnight courier service.

 

Table of Contents

Page 18

27 JANUARY 2002

Notices shall be deemed to have been received: if hand delivered, when so delivered; if
mailed, five days after deposit as certified or registered mail; if by courier, on the date
scheduled for delivery; and if by facsimile transmission, on the date shown on the confirmation of
the transmission generated by the sending machine. All notices shall be sent to the addresses and
facsimile numbers set forth below (or at such address or facsimile number as the receiving Party
may specify from time to time in accordance with this Section):

	 	 	 
	If to TOMOTHERAPY:

	 	If to ANALOGIC
	 
	 	 
	TOMOTHERAPY, Inc.

	 	ANALOGIC Corporation
	1240 Deming Way

	 	8 Centennial Drive
	Madison, WI 53717

	 	Peabody, MA 01960
	 
	 	 
	Attention: John J. Barni, CEO

	 	Attention:Lonnie Weaver
	 
	 	 
	Facsimile: 608-824-2996

	 	Facsimile: 978-977-6805
	 
	 	 
	with a copy to:

	 	with a copy to:
	 
	 	 
	La Follette Godfrey & Kahn

	 	General Counsel
	Attn: Michael E. Skindrud

	 	ANALOGIC Corporation
	One East Main Street

	 	8 Centennial Drive
	Madison, WI 53703

	 	Peabody, MA 01960
	 
	 	 
	Facsimile: 608-257-0609

	 	Facsimile: 978-977-6802

23. DISPUTE RESOLUTION

If a dispute arises out of or relates to this Agreement, or its breach, and the Parties have not
been successful in resolving such dispute through negotiation, the Parties agree to resolve the
dispute through binding arbitration in accordance to the rules of the American Arbitration
Association (“AAA”). Unless the Parties can agree to a sole arbitrator, there shall be three (3)
arbitrators, with each party appointing one arbitrator, who collectively will select a third. Each
party shall bear its own expenses and an equal share of the expenses of the arbitrator and the fees
of the AAA. The Parties, their representatives, other participants and the arbitrator(s) shall hold
the existence, content and result of the arbitration in confidence. This Agreement shall be
enforceable, and any arbitration award shall be final, and judgment thereon shall be entered into
any court of competent jurisdiction. Nothing in this clause shall be construed to preclude any
party from seeking injunctive relief in order to protect its rights pending arbitration. A request
by a party to a court for such injunctive relief shall not be deemed a waiver of the obligation to
arbitrate.

 

Table of Contents

Page 19

27 JANUARY 2002

If ANALOGIC initiates the arbitration process, the arbitration shall be held in
Milwaukee,Wisconsin. If TOMOTHERAPY initiates the arbitration process, the arbitration
shall be held in Boston, Massachusetts.

24. ASSIGNMENT

This Agreement shall be binding upon and inure to the benefit of the parties, their successors and
assigns. This Agreement shall not be assignable by either party without the prior written consent
of the other, which consent shall not be unreasonably refused, except that in the event that a
third party acquires substantially all assets of TOMOTHERAPY, TOMOTHERAPY may assign this agreement
without ANALOGIC’s consent provided that the third party agrees to be bound by all of the terms of
this Agreement, including but not limited to ANALOGIC’S right to be the exclusive supplier of all
items or Components it has designed; and that any ANALOGIC Technology so assigned will not be used
in the design and manufacture of substitutes for new or different versions of the Components.

25. GOVERNING LAW; SEVERABILITY

This Agreement shall be governed by and construed in accordance with the internal laws of the state
of New York. If any portion of this Agreement is found by a court of competent jurisdiction to be
illegal, invalid or unenforceable, such portion shall be deleted and all other terms and conditions
of this Agreement shall remain in full force and effect and shall be interpreted to achieve, to the
greatest extent possible, the objectives of this Agreement taken as a whole, including the illegal,
invalid or unenforceable provision.

26. PUBLICITY

Unless expressly approved in advance and in writing by the other party, neither party shall make
any reference to the other, but may do so as to the subject matter of this Agreement in any
publicity, advertising or other public statements or documents. Neither party will disclose to
others, without the other’s consent, the fact that it is acting on behalf of the others.

27. COUNTERPART

This Agreement may be executed in any number of counterparts, ANALOGIC of which shall be considered
an original and all of which shall constitute one and the same instrument.

28. NO THIRD PARTY BENEFICIARIES

Nothing in this Agreement is intended to create any rights by persons not a Party to this
Agreement and no other Party will be construed to be a third Party beneficiary of this
Agreement or otherwise have any legal or equitable rights as a result of this Agreement.

29. SURVIVAL

Notwithstanding the expiration or termination of this Agreement, Sections 11,12,13,14, 15, and
21,the rights that have been given to purchasers of the Products during the term(s) of this
Agreement to ANALOGIC Information and Proprietary Technology, TOMOTHERAPY Information and
Proprietary Technology, Development Information, and ANALOGIC

 

Table of Contents

Page 20

27 JANUARY 2002

Software, as well as such other provisions hereof where the sense and context so
admits, will survive in accordance with their terms.

30. MANUFACTURING RIGHTS

Notwithstanding, anything herein to the contrary, if at any time during the Agreement
there is a force majeure failure or inability on ANALOGIC’s part to deliver the
Components duly ordered by TOMOTHERAPY for a period of 60 days, and during this period of
time ANALOGIC fails to provide TOMOTHERAPY with a realistic plan for resumption of the
Components manufactured prior to the expiration of the ninetieth (90th) day
following failure to deliver the Components, then TOMOTHERAPY will have the manufacturing
rights to produce the Components until such time as ANALOGIC is reasonably capable of
resuming the manufacturing of the Components.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this
Agreement as of the Effective Date.

	 	 	 	 	 
	 	 	TOMOTHERAPY INCORPORATED a Wisconsin

corporation
	 
	 	 	 	 
	 

	 	By:
	 	/s/ John J. Barni
	 

	 	 	 	 
	 

	 	Title:
	 	CEO 2/4/03
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	ANALOGIC Corporation, a

Massachusetts corporation,
	 
	 	 	 	 
	 

	 	By:
	 	/s/ (illegible)
	 

	 	 	 	 
	 

	 	Title:
	 	CEO 2/5/03
	 

	 	 	 	 

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	1 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

Analogic-TomoTherapy Development and OEM

Supply Agreement

Exhibit 1: Specifications

	 	 	 	 	 	 	 	 	 
	Rev	 	CA No	 	Date	 	Comment	 	Originator
	0

	 	-
	 	4/24/02
	 	Initial revision — added PDU, Computers, disk
components to first contract for review
	 	D. Murray
	1

	 	-
	 	6/25/02
	 	Modifications following review by Bob Riemer,
Dave Murray, and many others
	 	D Murray
	2

	 	-
	 	1/14/03
	 	Modifications following phone discussion between Weaver, Riemer, Murray
	 	D Murray
	3

	 	-
	 	1/14/03
	 	Corrected issue with Section 10 heading
	 	D Murray
	4

	 	-
	 	1/20/03
	 	Change Exhibit 1 reference to Analogic family tree
	 	D Murray
	5

	 	-
	 	1/20/03
	 	Change Exhibit 1 reference to AN6500 (from
“TomoTherapy Gantry”)
	 	D Murray

COMPANY CONFIDENTIAL

This
document contains confidential or proprietary information of TomoTherapy, Inc.
Neither this document nor the information contained therein is to be reproduced,
distributed, used or disclosed, either in whole or in part, except as specifically
authorized by TomoTherapy, Inc.

 

TABLE OF CONTENTS

									

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	2 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

Table of Contents

	 	 	 	 	 	 	 	 	 	 	 
	1	 	Scope	 	 	4	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	1.1	 	Identification	 	 	4	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	1.2	 	Statement of System’s Intended Use	 	 	4	 
	 
	 	 	 	 	 	 	 	 	 	 
	2	 	Standards and Regulations	 	 	4	 
	 
	 	 	 	 	 	 	 	 	 	 
	3	 	Types of Users	 	 	5	 
	 
	 	 	 	 	 	 	 	 	 	 
	4	 	System Architecture	 	 	5	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	4.1	 	System Data Flow	 	 	7	 
	 
	 	 	 	 	 	 	 	 	 	 
	5	 	Gantry Subsystem Requirements	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	5.1	 	Scope	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	5.2	 	Functional Requirements	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.1	 	General	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.2	 	Gantry Frame	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.3	 	Gantry Mechanical	 	 	8	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.4	 	Gantry Component Mounting	 	 	9	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.5	 	Slip Ring System	 	 	9	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.6	 	Gantry Control	 	 	10	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	5.2.7	 	Data Communication	 	 	10	 
	 
	 	 	 	 	 	 	 	 	 	 
	6	 	Couch Subsystem Requirements	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	6.1	 	Scope	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	6.2	 	Functional Requirements	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	6.2.1	 	General	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	6.2.2	 	Mechanical	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	6.2.3	 	Control	 	 	11	 
	 
	 	 	 	 	 	 	 	 	 	 
	7	 	DAS Subsystem Requirements	 	 	13	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	7.1	 	Scope	 	 	13	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	7.2	 	Functional Requirements	 	 	13	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	7.2.1	 	General	 	 	13	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	7.2.2	 	Electronics	 	 	13	 
	 
	 	 	 	 	 	 	 	 	 	 
	8	 	Power Distribution Unit (PDU) Subsystem Requirements	 	 	14	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	8.1	 	Scope	 	 	14	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	8.2	 	Functional Requirements	 	 	14	 

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	3 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	8.2.1	 	General	 	 	14	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	8.2.2	 	Electrical	 	 	14	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	8.2.3	 	Control	 	 	15	 
	 
	 	 	 	 	 	 	 	 	 	 
	9	 	Control Computer Requirements	 	 	16	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	9.1	 	Scope	 	 	16	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	9.2	 	Functional Requirements	 	 	16	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	9.2.1	 	General	 	 	16	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	9.2.2	 	Stationary Controller (STC) Hardware	 	 	16	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	9.2.3	 	On-Board Controller (OBC) Hardware	 	 	17	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	9.2.4	 	Data Receiver Server (DRS) Hardware	 	 	17	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	9.2.5	 	Software Drivers	 	 	17	 
	 
	 	 	 	 	 	 	 	 	 	 
	10	 	Gantry Component Requirements	 	 	19	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	10.1	 	Scope	 	 	19	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	10.2	 	Functional Requirements	 	 	19	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	10.2.1	 	Circuit Boards	 	 	19	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	10.2.2	 	List of Gantry Components with Analogic Involvement	 	 	21	 

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	4 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

1 Scope

	 	1.1	 	Identification
	 
	 	 	 	The following subsystems are addressed by this document:

	 	•	 	TomoTherapy Hi-Art II Gantry Subsystem, including mounting of certain Analogic-
and TomoTherapy-supplied components.
	 
	 	•	 	TomoTherapy Hi-Art II Couch Subsystem.
	 
	 	•	 	TomoTherapy Hi-Art II DAS Subsystem.
	 
	 	•	 	TomoTherapy Hi-Art II Communications Subsystem.
	 
	 	•	 	TomoTherapy Hi-Art II Power Distribution Unit (PDU)
	 
	 	•	 	TomoTherapy Hi-Art II Control Computers

	 	1.2	 	Statement of System’s Intended Use
	 
	 	 	 	The TomoTherapy Hi•Art system is intended to be used to provide conformal
radiation therapy for patients who have been deemed acceptable candidates for
radiation treatment of cancer. Its purpose is to precisely deliver beams of
radiation, automatically tailored to the individual case, with immediate
verification.

2 Standards and Regulations

	 	 	 	The TomoTherapy Hi•Art System shall be designed to promote conformance with
design standards:

	 	•	 	IEC 60601-1: Medical Electric Equipment — Part 1: General Requirements for Safety
	 
	 	•	 	UL 2601-1: Medical Electrical Equipment, Part 1: General Requirements for Safety (USA version
of international requirements)
	 
	 	•	 	IEC 60601-1-2: Medical Electric Equipment — Part 1: General Requirements for Safety;
Electromagnetic Compatibility — Requirements and Tests
	 
	 	•	 	IEC 60601-1-4: Medical Electric Equipment — Part 1: General Requirements for Safety; 4.
Collateral Standard: Programmable Electrical Medical Systems
	 
	 	•	 	IEC 60601-2-1: Medical Electric Equipment — Part 2: Particular Requirements for Medical
Electron Accelerators in the Range 1 MeV to 50 MeV
	 
	 	•	 	IEC 61217: Radiotherapy equipment — coordinates, movements and scales (1996-08)
	 
	 	•	 	IEC/TR 62266 (2002-03): Medical electrical equipment: Guidelines for implementation of DICOM in
radiotherapy

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	5 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	•	 	ANSI/AAMI HE48: Human Factors Engineering Guidelines and Preferred Practices for the Design of
Medical Devices.

3 Types of Users

	 	•	 	Physicians/Oncologists
	 
	 	•	 	Technicians
	 
	 	•	 	Physicists
	 
	 	•	 	Service personnel

4 System Architecture

	 	The architecture for the TomoTherapy Hi•Art system can be broken down
into three major subsystems: 1) Planning subsystem, 2) Delivery subsystem, and 3)
Database server.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	6 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

Figure 1 System Architecture

[*]

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	7 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	4.1	 	System Data Flow
	 
	 	 	 	The figure below illustrates the flow of data between each component of the
HI•ART system. All data is accessed from, and saved to, the Database Server.
	 
	 	 	 	Figure 2 System Data Flow

[*]

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	8 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

5 Gantry Subsystem Requirements

	 	5.1	 	Scope

	 	 	 	The gantry subsystem includes the gantry frame, bearings, slip-rings, rotating
mounting plate, and data communication components.

	 	5.2	 	Functional Requirements

	 	5.2.1	 	General

	 	5.2.1.1	 	The gantry system shall conform to [*],
[*], and [*] when incorporating Analogic components.
	 
	 	5.2.1.2	 	Communication software between Analogic components needed for the
implementation of the TomoTherapy system shall be supplied, except for
3rd party development tools and environments that may be sourced
directly by TomoTherapy Inc.

	 	5.2.2	 	Gantry Frame

	 	5.2.2.1	 	The gantry frame shall be capable of supporting at least [*] kg with a safety
factor of at least [*].
	 
	 	5.2.2.2	 	The depth of the gantry frame shall be [*] mm or less.
	 
	 	5.2.2.3	 	The width of the gantry frame shall be [*] mm or less.
	 
	 	5.2.2.4	 	The maximum height of the entire gantry system shall be [*] mm or less.

	 	5.2.3	 	Gantry Mechanical

	 	5.2.3.1	 	The gantry shall be capable of rotating at a speed of up to [*] r.p.m.
	 
	 	5.2.3.2	 	The gantry bearing shall have a life exceeding [*] years normal clinical use at
[*] r.p.m., under a load of [*] kg cantilevered at [*] mm.
	 
	 	5.2.3.3	 	The gantry must be sufficiently rigid to hold the position of the detector to
within [*] ìm of the center of rotation, independently of gantry rotational
position.
	 
	 	5.2.3.4	 	[*]
	 
	 	5.2.3.5	 	[*]
	 
	 	5.2.3.6	 	[*]
	 
	 	5.2.3.7	 	The gantry motor drive shall be capable of providing a steady state torque of
at least [*] N.m. ([*] ft.lb).

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	9 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	5.2.3.8	 	The gantry motor drive shall also be capable of providing sufficient additional
torque to accelerate the fully-loaded gantry to the maximum specified rotation
speed in less than [*] seconds.
	 
	 	5.2.3.9	 	The gantry motor drive controller shall control the gantry position to within
[*] degree of the specified position.
	 
	 	5.2.3.10	 	The inside diameter of the unpopulated gantry before the external covers are
fitted shall be [*] cm or greater.

	 	5.2.4	 	Gantry Component Mounting

	 	5.2.4.1	 	Provision shall be made on the gantry for the mounting of the linear
accelerator, primary collimation system, collimating jaws, and multi-leaf
collimator.
	 
	 	5.2.4.2	 	Provision shall be made on the gantry for the mounting of the CT detector, DAS,
and associated power supplies.
	 
	 	5.2.4.3	 	Provision shall be made on the gantry for the mounting of a solid-state
modulator power supply, solid-state modulator, magnetron, circulator, and
associated electronics.
	 
	 	5.2.4.4	 	There must be sufficient space on the gantry for the mounting of a conventional
modulator and power supply instead of the solid-state modulator.
	 
	 	5.2.4.5	 	Space shall be available on the gantry for the mounting of the on board
computers.
	 
	 	5.2.4.6	 	Space shall be available on the gantry for the mounting of small low-voltage
power supplies to supply the various electrical components.
	 
	 	5.2.4.7	 	Provision shall be made on the gantry to allow for the routing of cooling pipes
or flexible tubing to and from the cooled components.
	 
	 	5.2.4.8	 	Provision shall be made on the gantry to allow for the routing of signal cables
to the electronic components.
	 
	 	5.2.4.9	 	Provision shall be made on the gantry to allow for the routing of power cables
to the electronic components, separated from the signal cables where possible.
	 
	 	5.2.4.10	 	Provision shall be made on the gantry to allow for the routing of compressed
air to the MLC assembly, including mounting of an accumulator tank.

	 	5.2.5	 	Slip Ring System

	 	5.2.5.1	 	The gantry slip-ring system shall support two-way Ethernet communication with a
data rate of at least [*] Mbit/sec, with necessary electronics provided to account
for transmission line effects.
	 
	 	5.2.5.2	 	The gantry slip-ring system shall provide [*] low-power, low voltage lines for
use in the hardware interlock system.
	 
	 	5.2.5.3	 	The gantry slip-ring system shall provide [*] power
rings ([*] signal, [*]
signal ground, [*] safety ground), capable of handling either [*] A per phase at
[*] V or [*] A per phase at [*] V.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	10 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	5.2.5.4	 	The gantry slip-ring system shall provide [*] spare low power, low voltage slip
ring.

	 	5.2.6	 	Gantry Control

	 	5.2.6.1	 	A gantry angle detection system shall be provided.
	 
	 	5.2.6.2	 	The instantaneous gantry angle to the within [*] degrees must be available to
the control software on the rotating side.
	 
	 	5.2.6.3	 	The gantry angle must be made available across the data communication system
(see below) with a known latency, to control stationary side components.

	 	5.2.7	 	Data Communication

	 	5.2.7.1	 	A one-way data transmission for sending DAS and monitor signal data from the
rotating side to the stationary side of the gantry shall be provided.
	 
	 	5.2.7.2	 	The data transmission system shall be capable of detecting and signaling data
transmission violation errors.
	 
	 	5.2.7.3	 	The data transmission system shall support transfer of up to [*] channels of
DAS data at up to [*] views per second.
	 
	 	5.2.7.4	 	The underlying data transmission system technology shall be
capable of transferring data fast enough to handle a multi-row
detector of at least [*] rows, [*] channels per
row, at [*] views per second.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	11 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

6 Couch Subsystem Requirements

	 	6.1	 	Scope
	 
	 	 	 	The couch (table) subsystem includes the physical patient support and the
control and
output electronics and software interfaces associated with it.
	 
	 	6.2	 	Functional Requirements

	 	6.2.1	 	General

	 	6.2.1.1	 	The couch system shall conform to [*], and [*], when incorporating Analogic
components.
	 
	 	6.2.1.2	 	Communication software between Analogic components needed for the
implementation of the TomoTherapy system shall be supplied, except
for 3rd party development tools and environments that may
be sourced directly by TomoTherapy Inc.

	 	6.2.2	 	Mechanical

	 	6.2.2.1	 	There shall be no metal structural members within the pallet
in the scan region.
	 
	 	6.2.2.2	 	The total longitudinal couch travel shall be at least
[*]m.
	 
	 	6.2.2.3	 	The maximum possible couch height when installed shall be no less than the
height of the machine isocenter, namely [*] cm. Additional “feet” may need to be
added to the couch by TomoTherapy or Analogic to achieve this.
	 
	 	6.2.2.4	 	The minimum possible couch height when installed shall be no greater than [*]
cm.
	 
	 	6.2.2.5	 	The couch width shall be that of a standard [*] couch, namely [*] cm.
	 
	 	6.2.2.6	 	The couch thickness shall be [*].
	 
	 	6.2.2.7	 	Total couch sag when maximally extended at a plane [*] mm from the cradle pivot,
relative to an unloaded couch, shall not exceed [*]mm when a load of [*]kg is
placed [*]mm from the cradle pivot.
	 
	 	6.2.2.8	 	In the case of couch failure, it shall be possible to release the couch pallet
and withdraw the patient from the gantry bore.

	 	6.2.3	 	Control

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	12 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	6.2.3.1	 	At any time, the absolute longitudinal position of the couch to within [*]μm shall be
available to control software via polling, at speeds of less than or equal to [*] mm/sec.
	 
	 	6.2.3.2	 	At any time, feedback on the absolute vertical position of the couch shall be available via
a [*].
	 
	 	6.2.3.3	 	It shall be possible to command the couch to move longitudinally at speeds as low as [*]
μm/sec.
	 
	 	6.2.3.4	 	It shall be possible to command the couch to move longitudinally at speeds as high as [*]
mm/sec.
	 
	 	6.2.3.5	 	The couch shall provide a software interface to allow a remote computer to
control its movements and poll for feedback.
	 
	 	6.2.3.6	 	The couch shall be capable of signaling the controlling computer via
hardware when an internal (watchdog) failure is detected.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	13 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

7 DAS Subsystem Requirements

	 	7.1	 	Scope
	 
	 	 	 	The DAS subsystem includes the electronics to convert the detector signals and
other rotating-side monitoring signals and provide it in a form that can be used by
the rest of the system.
	 
	 	7.2	 	Functional Requirements

	 	7.2.1	 	General

	 	7.2.1.1	 	The radiation therapy system shall conform to [*], [*], and [*], when
incorporating Analogic DAS components.
	 
	 	7.2.1.2	 	Communication software between Analogic components needed for the
implementation of the TomoTherapy system shall be supplied, except for
3rd party development tools and environments that may be sourced
directly by TomoTherapy Inc.

	 	7.2.2	 	Electronics

	 	7.2.2.1	 	The DAS shall support at least [*] detector channels.
	 
	 	7.2.2.2	 	The DAS shall support [*] additional data channels for other on-board signals
(some [*]V pulsed, some [*]V DC, some charge-based).
	 
	 	7.2.2.3	 	The DAS shall be designed to work with the [*], model number [*].
	 
	 	7.2.2.4	 	The DAS shall provide a minimum of [*] bits of resolution.
	 
	 	7.2.2.5	 	The DAS shall support view rates of [*] to [*] Hz.
	 
	 	7.2.2.6	 	[*]
	 
	 	7.2.2.7	 	[*]

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	14 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

8 Power Distribution Unit (PDU) Subsystem Requirements

	 	8.1	 	Scope
	 
	 	 	 	The PDU subsystem includes electrical components to isolate and transform mains
power, and distributing it to various components of the TomoTherapy Hi-Art II System.
	 
	 	8.2	 	Functional Requirements

	 	8.2.1	 	General

	 	8.2.1.1	 	The PDU shall be certified and labeled to comply with [*], [*], [*].

	 	8.2.2	 	Electrical

	 	8.2.2.1	 	The PDU shall accept the following AC 3-phase input voltages at [*]Hz:
[*]V, [*]V, [*]V, [*]V and [*]V.
	 
	 	8.2.2.2	 	For each allowable input voltage, a constant input voltage shall result in the
nominal [*] output having a value between [*]% and [*]% of the [*]V value.
	 
	 	8.2.2.3	 	For each allowable input voltage, a constant input voltage shall result in the
nominal [*] output having a value between [*]% and [*]% of the [*]V value.
	 
	 	8.2.2.4	 	There shall be a circuit breaker on the input side of the transformer,
accessible from outside the PDU. All output side breakers shall not be accessible
from outside the PDU.
	 
	 	8.2.2.5	 	The PDU shall be rated for [*]% duty cycle on all outputs.
	 
	 	8.2.2.6	 	The PDU shall provide [*]A at [*]VAC (3-phase) with a circuit breaker, for
powering the gantry slip rings. A neutral and a safety ground shall also be
supplied.
	 
	 	8.2.2.7	 	The PDU shall provide [*]A at [*] VAC (3-phase), with a circuit breaker, for
powering the compressor.
	 
	 	8.2.2.8	 	The PDU shall provide [*]A at [*] VAC (3-phase), with a circuit breaker for
powering the pump stand.
	 
	 	8.2.2.9	 	The PDU shall provide sufficient power, with a circuit breaker, for powering
the couch supplied by Analogic.
	 
	 	8.2.2.10	 	The PDU shall provide sufficient power, with a circuit breaker, for powering
the gantry drive supplied by Analogic.
	 
	 	8.2.2.11	 	The PDU shall provide a total of [*]A at [*] VAC (single phase) over 3
outlets, each with a circuit breaker, for powering the Stationary Controller
(STC), lasers, and gantry display.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	15 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	8.2.2.12	 	The PDU shall provide [*]A at [*] VAC (single phase), with a circuit breaker,
for powering the Data Receiver Server (DRS). This supply shall be protected by an
uninterruptible power supply (UPS), delivering the rated load for a minimum of
[*] minutes.
	 
	 	8.2.2.13	 	The PDU shall provide [*]A at [*] VAC (single phase), with a circuit breaker,
for powering the Operator Station and monitor.
	 
	 	8.2.2.14	 	The PDU shall provide [*] ingress protection per [*].
	 
	 	8.2.2.15	 	All power connections to the PDU shall be either hard-wired, or locking-type
plugs.
	 
	 	8.2.2.16	 	The PDU shall monitor output voltage on the [*] outputs, and provide an
output signal indicating whether or not the voltage is within [*]% to [*]% of
the nominal value.

	 	8.2.3	 	Control

	 	8.2.3.1	 	The PDU shall be capable of disabling power to the disk in response to an
external control signal (the “disk off” signal).
	 
	 	8.2.3.2	 	The PDU shall provide an output signal that indicates the status of the power
phases.
	 
	 	8.2.3.3	 	The PDU outputs shall not be able to be turned on unless an external key
switch control signal is active.
	 
	 	8.2.3.4	 	The PDU shall remove power from the outputs in response to either of two
external control signals (the “off” or “key enable” signals).
	 
	 	8.2.3.5	 	The PDU outputs shall turn on if both of two external control signals (the
“key enable” and “system on” signals) are active.
	 
	 	8.2.3.6	 	The PDU shall open the main input-side breaker in response to
[*] (the “[*]”).
	 
	 	8.2.3.7	 	The PDU outputs shall not provide output power unless [*] (the “[*]”) is connected.
	 
	 	8.2.3.8	 	The PDU shall provide [*], [*] (for operating the door indicator system).
	 
	 	8.2.3.9	 	The PDU shall provide a [*]. The PDU shall provide [*].

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	16 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

9 Control Computer Requirements

	 	9.1	 	Scope
	 
	 	 	 	The Control Computers include the computer chassis, boards, and software
components needed to control the operation of the TomoTherapy Hi-Art II delivery
subsystem. The control computers include: On-board Controller (OBC), Stationary
Controller (SBC), and Data Receiver Server (DRS).
	 
	 	9.2	 	Functional Requirements

	 	9.2.1	 	General

	 	9.2.1.1	 	All circuit boards used in the control computers shall be certified to [*], and
be labeled as such.
	 
	 	9.2.1.2	 	All circuit boards used in the control computers shall be designed to standards
[*] and [*].
	 
	 	9.2.1.3	 	The control computers shall consist of three separate boxes: the Stationary
Controller (STC); On-Board Controller (OCB), and Data Receiver Server (DRS).
	 
	 	9.2.1.4	 	The control computers shall each have status indicators indicating if the
computer is functioning normally or in one or more error states.
	 
	 	9.2.1.5	 	The control computers shall each be constructed in a manner consistent with the
requirements of [*].
	 
	 	9.2.1.6	 	The control computers shall each be supplied with one [*].
	 
	 	9.2.1.7	 	On each compute, Analogic shall pre-install a [*] and [*]. Alternatively,
Analogic shall install a [*] supplied by TomoTherapy if and when it becomes
available. The software supplied to Analogic will be subject to change, but shall
be provided by TomoTherapy in a controlled way and with sufficient notice to allow
integration into Analogic’s manufacturing process.

	 	9.2.2	 	Stationary Controller (STC) Hardware

	 	9.2.2.1	 	The STC shall provide I/O lines to control the gantry motor drive, supplied by
Analogic.
	 
	 	9.2.2.2	 	The STC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.2.3	 	The STC shall provide an Ethernet connection to the delivery subsystem
communications network and gantry displays.
	 
	 	9.2.2.4	 	The STC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.2.5	 	The STC shall provide hardware I/O lines to interface with the [*].

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	17 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	9.2.2.6	 	The STC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.2.7	 	The STC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.2.8	 	The STC shall provide hardware I/O lines to interface with the [*], supplied by [*].
	 
	 	9.2.2.9	 	The STC shall provide hardware I/O lines to interface with [*] and [*] for [*] and [*].

	 	9.2.3	 	On-Board Controller (OBC) Hardware

	 	9.2.3.1	 	The OBC shall be able to operate correctly when rotating at speeds between and including [*] r.p.m. and [*] r.p.m.
	 
	 	9.2.3.2	 	The OBC shall provide Ethernet connection to the delivery
subsystem communications network.
	 
	 	9.2.3.3	 	The OBC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.3.4	 	The OBC shall provide hardware I/O lines to interface with the [*].
	 
	 	9.2.3.5	 	The OBC shall provide hardware I/O lines to interface with the  [*] ([*]) subsystem.
	 
	 	9.2.3.6	 	The OBC shall provide hardware I/O lines to interface with the [*]  ([*]) subsystem.
	 
	 	9.2.3.7	 	The OBC shall provide an interface to the [*] ([*]) subsystem, supplied by [*].
	 
	 	9.2.3.8	 	The OBC shall provide electronics to prepare the [*] and [*] for transfer over the high
speed data transmission system, supplied by [*].

	 	9.2.4	 	Data Receiver Server (DRS) Hardware

	 	9.2.4.1	 	The DRS shall provide an Ethernet connection to the delivery subsystem communications
network.
	 
	 	9.2.4.2	 	The DRS shall provide a separate Ethernet port for connection to the external
communications network (of which the TomoTherapy Hi-Art II Operator Station forms a part).
	 
	 	9.2.4.3	 	The DRS shall provide electronics to receive the [*] and [*] transferred over the high
speed data transmission system, supplied by [*].
	 
	 	9.2.4.4	 	The DRS shall provide a set of [*] ([*]), that can be used to implement [*] on [*] that are
received from the [*].

	 	9.2.5	 	Software Drivers
	 
	 	 	 	The following software drivers shall be supplied by Analogic with a royalty-free
license to use on the TomoTherapy Hi-Art II System:

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	18 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	 	 
	9.2.5.1
	 	[*]
	 
	 	 
	9.2.5.2
	 	[*]
	 
	 	 
	9.2.5.3
	 	[*]
	 
	 	 
	9.2.5.4
	 	[*]
	 
	 	 
	9.2.5.5
	 	[*]
	 
	 	 
	9.2.5.6
	 	[*]
	 
	 	 
	9.2.5.7
	 	[*]
	 
	 	 
	9.2.5.8
	 	[*]

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	19 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

Gantry Component Requirements

	 	10.1	 	Scope
	 
	 	 	 	Analogic will supply a number of components on the gantry subsystem when delivered to
TomoTherapy. These components include, but are not limited to, power supplies, circuit
breakers, cables, and circuit boards. Analogic will perform the following tasks in
relation to this work:

	 	•	 	Developing, along with TomoTherapy, the system design.
	 
	 	•	 	Selecting and/or sourcing the components (see Section 10.2.2 below).
	 
	 	•	 	Designing and developing components (see Section 10.2.2 below).
	 
	 	•	 	Developing control software for selected components (as
described in Exhibit 2, “Milestones”).
	 
	 	•	 	Fabricating, assembling, and integrating the Analogic portion
of the Hi-Art II prototype subsystem.
	 
	 	•	 	Assisting TomoTherapy with integration of the
Analogic-developed portion of the Hi-Art II prototype with the
TomoTherapy-developed portion of the Hi-Art II prototype.

	 	10.2	 	Functional Requirements

	 	10.2.1	 	Circuit Boards
	 
	 	 	 	Based upon TomoTherapy requirements specifications, Analogic shall design and
manufacture the following circuit boards for use in the TomoTherapy Hi-Art II System:

	 	10.2.1.1	 	MLC Control Board
	 
	 	 	 	The MLC Control Board provides an interface from the [*] to the [*]. The
board isolates the [*] signals from and routes power to the [*].

	 	10.2.1.2	 	PDU and Interlock Control Board

	 	•	 	The PDU and Interlock Control Board provides an interface to the
[*], [*] and [*]. It forwards the [*] to the [*] to disable the [*]
and [*]. It also forwards the signal to the [*]
to turn off the disk power.
	 
	 	•	 	The PDU and Interlock Control Board also interfaces with the [*]
to break or make the interlock depending on the status of the [*]
from the [*]. The status of the door interlock is [*].

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	20 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	•	 	The PDU and Interlock Control Board provides an interface to the
[*] with the [*] to allow it to make and break the interlock. The
[*] can also read the interlock status from the board. The board
also requires the computers to send a [*].
	 
	 	•	 	The PDU and Interlock Control Board provides an interface to [*]
to allow [*] to any one of [*] preconfigured angles of [*],[*],[*],
and [*] degrees.

	 	10.2.1.3	 	Linac Moderator Interface Board
	 
	 	 	 	The linac modulator interface board provides an interface from the [*]
to the [*], [*], [*], and [*]. In response to signals from the [*], it
controls [*] to the linac subsystem. Also, a high voltage
interlock circuit on this board is connected to the high voltage
interlock line, and
will [*] and [*] when the [*] [*].
	 
	 	10.2.1.4	 	AUX Input Board
	 
	 	 	 	The AUX Board provides an interface from the [*] to the [*]. It also monitors
[*] and [*] and [*] when [*] specified values.
	 
	 	 	 	Signals processed by the AUX board include:

	 	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]
	 
	 	 
	[*]
	 	[*]

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

	 	 	 	 	 	 	 	 	 
	Document No.	 	Document Name	 	Revision No.	 	Page
	 

	 	ANALOGIC-TOMOTHERAPY	 	 	 	 	 	 
	-

	 	DEVELOPMENT AND OEM SUPPLY
	 	 	5	 	 	21 OF 21
	 

	 	AGREEMENT — EXHIBIT 1	 	 	 	 	 	 

	 	 	 	 
	 
	 

	 	 	[*]
	 

	[*]	 	[*]
	 

	[*]	 	[*]

	 	10.2.1.5	 	Detector Gang Boards
	 
	 	 	 	The detector gang boards interface between the [*] (model number [*]) backplane and
the detector cables that lead to the Analogic DAS. Each board combines [*] backplane
connectors ([*] channels) into a single [*] connector.

	 	10.2.2	 	List of Gantry Components with Analogic Involvement
	 
	 	 	 	In addition to the circuit boards, Analogic will supply other components and cables to
be mounted on the gantry prior to shipment.
	 
	 	 	 	The document in Exhibit lb ([*], [*], Analogic
document number [*]) defines the components that will have Analogic
involvement, including the circuit boards described above.
	 
	 	 	 	For each component, Analogic will either manufacture the component, or source the
component directly. In either case the cost of the component will be included in the
Analogic quoted price. The component will be mounted on the [*] gantry by Analogic
prior to shipment (some of the components may be unmounted before shipping as agreed by
both parties).
	 
	 	 	 	TomoTherapy will provide Analogic with a [*] assembly (TomoTherapy assembly part number
[*]), which includes the [*] and [*] adjustors. These components will be mounted on the
[*] gantry by Analogic before shipment.

	 	 	 
	 
	QUALITY RECORD, Template F4-18 REV A

	 	TomoTherapy, Inc.
	Verify Latest Revision Before Using

	 	COMPANY CONFIDENTIAL

 

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

I. Original Agreement

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	1
	 	Contract Signing	 	$	[*]	 	 	10/01
	 
	 	 	 	 	 	 	 	 
	2
	 	Delivery of Rotating Test Bed	 	$	[*]	 	 	1/02
	 
	 	 	 	 	 	 	 	 
	3
	 	Design Review	 	$	[*]	 	 	10/01
	 
	 	 	 	 	 	 	 	 
	4
	 	Delivery of Table #1	 	$	[*]	 	 	10/01
	 
	 	 	 	 	 	 	 	 
	5
	 	Delivery of DAS #1	 	$	[*]	 	 	1/02
	 
	 	 	 	 	 	 	 	 
	6
	 	Delivery of Rx/PTM #1	 	$	[*]	 	 	5/02
	 
	 	 	 	 	 	 	 	 
	7
	 	Delivery of DAS #2	 	$	[*]	 	 	3/02
	 
	 	 	 	 	 	 	 	 
	8
	 	Delivery of Rx/PTM #2	 	$	[*]	 	 	5/02
	 
	 	 	 	 	 	 	 	 
	9
	 	Delivery of DAS #3	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	10
	 	Delivery of Rx/PTM #3	 	$	[*]	 	 	9/02
	 
	 	 	 	 	 	 	 	 
	11
	 	Delivery of Table #2	 	$	[*]	 	 	2/02
	 
	 	 	 	 	 	 	 	 
	12
	 	Delivery of Table #3	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	13
	 	Delivery of Gantry #1	 	$	[*]	 	 	3/02
	 
	 	 	 	 	 	 	 	 
	14
	 	Delivery of Gantry #2	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	15
	 	Delivery of Gantry #3	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

1

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

II. Extension #1 — Power Distribution Units

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	16
	 	Upon Agreement of PDU Extension:	 	 	 	 	 	 
	 
	 	• PDU NRE #1	 	$	[*]	 	 	12/01
	 
	 	 	 	 	 	 	 	 
	17
	 	Upon Delivery of PDU # 1:	 	 	 	 	 	 
	 
	 	• PDU NRE #2	 	$	[*]	 	 	4/02
	 
	 	• PDU #1	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	18
	 	Upon Regulatory Approval:	 	 	 	 	 	 
	 
	 	• PDU NRE #3	 	$	[*]	 	 	9/02
	 
	 	 	 	 	 	 	 	 
	19
	 	Upon Delivery of PDU #2	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	20
	 	Upon Delivery of PDU #3	 	$	[*]	 	 	9/02
	 
	 	 	 	 	 	 	 	 
	21
	 	Upon Delivery of PDU #4	 	$	[*]	 	 	11/02
	 
	 	 	 	 	 	 	 	 
	22
	 	Upon Delivery of PDU #5	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	23
	 	Upon Delivery of PDU #6	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	24
	 	Upon Delivery of PDU #7	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	25
	 	Upon Delivery of PDU #8	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	26
	 	Upon Delivery of PDU #9	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	27
	 	Upon Delivery of PDU #10	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

III. Extension #2 — Disk Casting for Test Bed

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	28
	 	Disk Casting for Test Bed	 	 	[*]	 	 	1/02
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	 	[*]	 	 	 

2

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

IV. Extension #3 — Computers

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	29
	 	Upon Agreement of Computers Extension:	 	 	 	 	 	 
	 
	 	•   Computer Hardware NRE # 1	 	$	[*]	 	 	1/02
	 
	 	•   Computer Software NRE #1	 	$	[*]	 	 	1/02
	 
	 	 	 	 	 	 	 	 
	30
	 	Upon Partial Delivery of Development Computer Set #1	 	$	[*]	 	 	12/01
	 
	 	 	 	 	 	 	 	 
	31
	 	Upon Completion of Development Computer Set #1:	 	 	 	 	 	 
	 
	 	•   Prototype OBC	 	 	 	 	 	3/02
	 
	 	•   Prototype STC	 	$	[*]	 	 	8/02
	 
	 	•   Computer Hardware NRE #2	 	$	[*]	 	 	4/02
	 
	 	 	 	 	 	 	 	 
	32
	 	Upon Completion of Software
Training Workshops:	 	 	 	 	 	 
	 
	 	•   Computer Software NRE #2	 	$	[*]	 	 	3/02
	 
	 	 	 	 	 	 	 	 
	33
	 	Upon Delivery of Computer Set #2:	 	 	 	 	 	 
	 
	 	•   Computer Set #2	 	$	[*]	 	 	5/02
	 
	 	•   Rx/PTM #1 Credit (See Milestone # 6)	 	$	[*]	 	 	5/02
	 
	 	•   Computer Hardware NRE #3	 	$	[*]	 	 	5/02
	 
	 	 	 	 	 	 	 	 
	34
	 	Upon Delivery of Computer Set #3	 	 	 	 	 	 
	 
	 	•   Computer Set #3	 	$	[*]	 	 	5/02
	 
	 	•   Rx/PTM #2
Credit (See Milestone #8)	 	$	[*]	 	 	5/02
	 
	 	 	 	 	 	 	 	 
	35
	 	Upon Delivery of Computer Set #4	 	 	 	 	 	 
	 
	 	•   Computer Set #4	 	$	[*]	 	 	9/02
	 
	 	•   Rx/PTM #3 Credit (See Milestone # 10)	 	$	[*]	 	 	9/02
	 
	 	 	 	 	 	 	 	 
	36
	 	Upon Delivery of Computer Set #5	 	$	[*]	 	 	11/02
	37
	 	Upon Delivery of Computer Set #6	 	$	[*]	 	 	12/02
	38
	 	Upon Delivery of Computer Set #7	 	$	[*]	 	 	 
	39
	 	Upon Delivery of Computer Set #8	 	$	[*]	 	 	 
	40
	 	Upon Delivery of Computer Set #9	 	$	[*]	 	 	 
	41
	 	Upon Delivery of Computer Set #10	 	$	[*]	 	 	 
	42
	 	Upon Completion of Computer Software Support	 	 	 	 	 	 
	 
	 	•   Computer Software NRE #3	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	Subtotal	 	$	[*]	 	 	 

3

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03 

Exhibit 2: Milestones/Payments

V.
Extension #4 — Additional Gantries, Tables, and DAS’s

	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	Date Billed
	 
	 	 	 	 	 	 
	43
	 	Delivery of Gantry #4	 	$[*]	 	9/02
	 
	 	 	 	 	 	 
	44
	 	Delivery of Table #4	 	$[*]	 	11/02
	 
	 	 	 	 	 	 
	45
	 	Delivery of DAS #4	 	$[*]	 	11/02
	 
	 	 	 	 	 	 
	46
	 	Delivery of Gantry #5	 	$[*]	 	9/02
	 
	 	 	 	 	 	 
	47
	 	Delivery of Table #5	 	$[*]	 	 
	 
	 	 	 	 	 	 
	48
	 	Delivery of DAS #5	 	$[*]	 	12/02
	 
	 	 	 	 	 	 
	49
	 	Delivery of Gantry #6	 	$[*]	 	11/02
	 
	 	 	 	 	 	 
	50
	 	Delivery of Table #6	 	$[*]	 	 
	 
	 	 	 	 	 	 
	51
	 	Delivery of DAS #6	 	$[*]	 	 
	 
	 	 	 	 	 	 
	52
	 	Delivery of Gantry #7	 	$[*]	 	12/02
	 
	 	 	 	 	 	 
	53
	 	Delivery of Table #7	 	$[*]	 	 
	 
	 	 	 	 	 	 
	54
	 	Delivery of DAS #7	 	$[*]	 	 
	 
	 	 	 	 	 	 
	55
	 	Delivery of Gantry #8	 	$[*]	 	 
	 
	 	 	 	 	 	 
	56
	 	Delivery of Table #8	 	$[*]	 	 
	 
	 	 	 	 	 	 
	57
	 	Delivery of DAS #8	 	$[*]	 	 
	 
	 	 	 	 	 	 
	58
	 	Delivery of Gantry #9	 	$[*]	 	 
	 
	 	 	 	 	 	 
	59
	 	Delivery of Table #9	 	$[*]	 	 
	 
	 	 	 	 	 	 
	60
	 	Delivery of DAS #9	 	$[*]	 	 
	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	Subtotal	 	$[*]	 	 

4

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

VI. Extension #5 — Partial System Development and Manufacture

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	61
	 	Upon Agreement	 	 	 	 	 	 
	 
	 	• System NRE #1	 	$	[*]	 	 	3/02
	 
	 	 	 	 	 	 	 	 
	62
	 	System Design Review	 	 	 	 	 	 
	 
	 	• System NRE #2	 	$	[*]	 	 	7/02
	 
	 	 	 	 	 	 	 	 
	63
	 	Completion of First 3 Man Months Software Development	 	 	 	 	 	 
	 
	 	• System Software NRE #1	 	$	[*]	 	 	5/02
	 
	 	 	 	 	 	 	 	 
	64
	 	Completion of Second 3 Man Months Software Development	 	 	 	 	 	 
	 
	 	• System Software NRE #2	 	$	[*]	 	 	7/02
	 
	 	 	 	 	 	 	 	 
	65
	 	Assembly of Gantry Subsystem #1 at Analogic	 	 	 	 	 	 
	 
	 	• System NRE #3	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 	 
	66
	 	Completion of Third 3 Man Months Software Development	 	 	 	 	 	 
	 
	 	• System Software NRE #3	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 	 
	67
	 	Test Bed Hardware Integration of Analogic and TomoTherapy	 	 	 	 	 	 
	 
	 	Subsystems	 	 	 	 	 	 
	 
	 	• System NRE #4	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 	 
	68
	 	Delivery of Integrated Gantry Subsystem #1	 	$	[*]	 	 	9/02
	69
	 	Delivery of Integrated Gantry Subsystem #2	 	$	[*]	 	 	11/02
	70
	 	Delivery of Integrated Gantry Subsystem #3	 	$	[*]	 	 	12/02
	71
	 	Delivery of Integrated Gantry Subsystem #4	 	$	[*]	 	 	 
	72
	 	Delivery of Integrated Gantry Subsystem #5	 	$	[*]	 	 	 
	73
	 	Delivery of Integrated Gantry Subsystem #6	 	$	[*]	 	 	 
	74
	 	Delivery of Integrated Gantry Subsystem #7	 	$	[*]	 	 	 
	75
	 	Delivery of Integrated Gantry Subsystem #8	 	$	[*]	 	 	 
	76
	 	Delivery of Integrated Gantry Subsystem #9	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

5

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

VII. Extension #6 — Disk Casting Machining Modifications

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	77
	 	Lot Charge (9 Disks)	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

VIII. Extension #7 — Add Pneumatic Seal to Bearings

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	78
	 	Delivery of Prototype Bearing #1	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	79
	 	Delivery of Prototype Bearing #2	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

IX. Extension #8 — 100 VxWorks Target Licenses

	 	 	 	 	 	 	 	 	 
	Milestone #	 	Description	 	Payment Amount	 	 	Date Billed
	 
	 	 	 	 	 	 	 	 
	80
	 	15 Target Licenses (Computer Sets #1 - #5)	 	$	[*]	 	 	10/02
	 
	 	 	 	 	 	 	 	 
	81
	 	3 Target Licenses (Computer Set #6)	 	$	[*]	 	 	12/02
	 
	 	 	 	 	 	 	 	 
	82
	 	3 Target Licenses (Computer Set #7)	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	83
	 	3 Target Licenses (Computer Set #8)	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	84
	 	3 Target Licenses (Computer Set #9)	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	85
	 	3 Target Licenses (Computer Set #10)	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 	 
	86
	 	70 Target Licenses (@ $[*]/license)	 	$	[*]	 	 	 
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	                      Subtotal	 	$	[*]	 	 	 

6

Table of Contents

Analogic-TomoTherapy Development and OEM Supply

Agreement 1/14/03

Exhibit 2: Milestones/Payments

X.     Extension #9 — Gantry Power Interface Upgrade Kits

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Payment	 	 	Date
	Milestone #	 	Description	 	Amount	 	 	Billed
	 
	 	 	 	 	 	 	 	 
	87
	 	Gantry Power Interface Kit #1	 	$	[*]	 	 	12/02
	 
	 	 	 	 	 	 	 	 
	88
	 	Gantry Power Interface Kit #2	 	$	[*]	 	 	12/02
	 
	 	 	 	 	 	 	 	 
	89
	 	15:1 Gear Reducer	 	$	[*]	 	 	12/02
	 
	 	 	 	 	 	 	 	 
	90
	 	NRE	 	$	[*]	 	 	12/02
	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	Subtotal
	 	$	[*]	 	 	 

7

Table of Contents

TOMOTHERAPY SPARES

	 	 	 	 	 	 	 
	Part #	 	Description	 	Quantity	 	Price (each)
	10-42956-01

	 	Recon Computer Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60165-01

	 	PDU Control Board 00B
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-41954-01

	 	Base Control Comptr Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60204-01

	 	MLC Control Board
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60274-01

	 	Sensor Bd Cal Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60274-02

	 	Sensor Bd, Tick
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60019-01

	 	Gang Bd Assy Tested (8)
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60113-01

	 	Gang Bd Offset 2 Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60112-01

	 	Gang Bd Offset 1 Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60276-01

	 	Modulator Interface Bd 00D
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-60399-01

	 	Aux Input Bd Rev 1
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-44771-01

	 	Disk Control Assy
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-27160-01

	 	RTS DAS
	 	[*]
	 	$[*]
	 
	 	 	 	 	 	 
	10-42363-01

	 	Table Control Assy
	 	[*]
	 	$[*]

Notes:

Spares available until forecast from TomoTherapy and production ramp.

 

Table of Contents

Exhibit 3 — Production System Pricing (24 January 2003)

System is defined as of 12 August 2002 to include:

Gantry

Table

DAS

Computers (2- control and 1- reconstruction ) PDU

Commercial Components Cables

PCB’s, Chassis, Mounting Hardware

*System Assembly/ Integration / Test

* Does not include:

LINAC, Magnetron, SSM, HVPS

MLC and Jaws

Xenon Detectors

Rotary Union

System Covers

System workstation

System quantity pricing is based upon a quantity ordered and delivery accepted within the following
12 month period. This Production Systems Pricing will commence with the shipment of a production
HI-ART-II system (system #11) and will apply to all production systems.

Production System Pricing

	 	 	 	 	 
	1-19	 	20-49	 	50- UP
	$[*]
	 	$[*]
	 	$[*]

Pre-production System Pricing

Pilot systems #1 thru #10 = $[*] each

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]